

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

# Metabolomic applications in stem cell research: a review

Daniela S.C. Bispo<sup>1</sup>, Catarina S. H. Jesus<sup>1</sup>, Inês M. C. Marques<sup>1</sup>, Katarzyna M. Romek<sup>1</sup>, Mariana B. Oliveira<sup>1</sup>, João F. Mano<sup>1</sup>, Ana M. Gil<sup>1,\*</sup>

<sup>1</sup>CICECO - Aveiro Institute of Materials (CICECO/UA), Department of Chemistry, University of Aveiro, Campus Universitario de Santiago, 3810-193 Aveiro, Portugal

\* Author to whom correspondence should be addressed:  
Ana M. Gil, CICECO - Aveiro Institute of Materials (CICECO/UA), Department of Chemistry, University of Aveiro, Campus Universitario de Santiago, 3810-193 Aveiro, Portugal; Tel: +351 234370707, E-mail: agil@ua.pt

**Keywords:** stem cells; biomaterials; tissue regeneration; metabolomics; metabonomics; nuclear magnetic resonance; mass spectrometry; metabolite profiling

1	<b>Index</b>	
2	Abstract.....	3
3	Abbreviations.....	3
4	1. Introduction.....	5
5	2. Cell metabolomics and brief overview of applications in stem cell research.....	5
6	3. Metabolomics of mesenchymal stem cells (MSCs).....	7
7	3.1. Metabolic profile variability between tissue sources and donors.....	7
8	3.2. Differentiation.....	8
9	3.2.1. Adipogenesis.....	8
10	3.2.2. Osteogenesis.....	10
11	3.2.3. Differentiation into other lineages.....	12
12	3.3. Culture conditions.....	13
13	3.4. Aging, senescence, and autophagy.....	14
14	4. Metabolomics of pluripotent stem cells (iPSCs and ESCs).....	14
15	4.1. Metabolic remodelling during pluripotency acquisition.....	14
16	4.2. Differentiation.....	15
17	4.3. Culture conditions.....	16
18	4.4. Disease models.....	16
19	5. Metabolomics of neural stem cells (NSCs).....	17
20	5.1. Differentiation.....	17
21	5.2. Culture conditions.....	18
22	6. Metabolomics of other SCs.....	18
23	6.1. Differentiation.....	18
24	6.2. Other studies.....	19
25	Future perspectives.....	20
26	Acknowledgments.....	21
27	Declarations.....	21
28	Figure captions.....	22
29	Tables.....	25
30	References.....	26
31		
32		
33		
34		
35		
36		
37		
38		

## 1 **Abstract**

2 This review describes the use of metabolomics to study stem cell (SC) characteristics and function (excluding SCs in cancer research, suited to a fully dedicated text). The interest in employing  
3 metabolomics in SC research has consistently grown and emphasis is, here, given to developments  
4 reported in the past five years. This text informs on the existing methodologies and their complementarity regarding the information provided, comprising untargeted/targeted approaches, which couple  
5 mass spectrometry or nuclear magnetic resonance spectroscopy with multivariate analysis (and, in  
6 some cases, pathway analysis and integration with other omics), and more specific analytical approaches, namely isotope tracing to highlight particular metabolic pathways, or in tandem microscopic  
7 strategies to pinpoint characteristics within a single cell. The bulk of this review covers the existing  
8 applications in various aspects of mesenchymal SC behavior, followed by pluripotent and neural SCs,  
9 with a few reports addressing other SC types. Some of the central ideas investigated comprise the metabolic/biological impacts of different tissue/donor sources and differentiation conditions, including the  
10 importance of considering 3D culture environments, mechanical cues and/or media enrichment to  
11 guide differentiation into specific lineages. Metabolomic analysis has considered cell endometabolomes and exometabolomes (fingerprinting and footprinting, respectively), having measured both lipid  
12 species and polar metabolites involved in a variety of metabolic pathways. This review clearly demonstrates the current enticing promise of metabolomics in significantly contributing towards a deeper  
13 knowledge on SC behavior, and the discovery of new biomarkers of SC behavior and function with  
14 potential translation to *in vivo* clinical practice.  
15  
16  
17  
18  
19  
20  
21

## 22 **Abbreviations**

23 **AA**, arachidonic acid; **ADA**, alginate di-aldehyde; **ALA**,  $\alpha$ -linolenic acid; **AST**, astaxanthin; **BMP-2**,  
24 bone morphogenetic protein 2; **CE**, capillary electrophoresis; **CNS**, central nervous system; **CoA**,  
25 coenzyme A; **DAG**, diacylglycerols; **Dex**, dexamethasone; **DFO**, desferrioxamine; **DHA**, docosahex-  
26 aenoic acid; **DI**, direct infusion; **DPSCs**, dental pulp; **EBs**, embryoid bodies; **ECM**, extracellular matrix;  
27 **EFs**, embryonic fibroblasts; **EpSCs**, epidermal Stem cells; **ESCs**, Embryonic stem cells; **FAs**,  
28 fatty acids; **FLS**, fibroblast-like synoviocyte; **GC**, gas chromatography; **GdnF**, Glial cell line-derived  
29 neurotrophic factor; **GHK**, glycine-histidine-lysine; **GPC**, glycerophosphocholine; **GPMVs**, of giant  
30 plasma membrane vesicles; **GWAS**, Genome-Wide-Association-Studies; **hAMSCs**, Human adipose-  
31 derived mesenchymal stem cells; **hBMMSCs**, Human bone marrow mesenchymal stem cells;  
32 **hBTSCs**, human biliary tree stem/progenitor cells; **hHBs**, human hepatoblasts; **hHpSCs**, hepatic stem  
33 cells; **hPDLSCs**, Human periodontal ligaments stem cells ; **hPMSCs**, Human placenta-derived mes-  
34 enchymal stem cells; **hPSC-CMs**, Cardiomyocytes derived from human pluripotent stem cell;  
35 **HRMAS**, high resolution magic angle spinning; **HSCs**, haematopoietic stem cells; **hSGSCs**, Human  
36 salivary gland stem cells; **htt**, Huntington locus; **IB**, inclusion bodies; **IFN- $\gamma$** , interferon gamma ; **ILK**,  
37 integrin linked kinase; **iMSCs**, mesenchymal stem cells derived from iPSCs; **iPSCs**, induced pluripo-  
38 tent stem cells; **LA**, linoleic acid; **LC**, liquid chromatography; **LIPUS**, low-intensity pulsed ultra-  
39 sound; **mESCs**, murine Embryonic stem cells; **MRI**, magnetic resonance imaging; **MS**, Mass Spec-

1 trometry; **MSC**, Mesenchymal stem cell; **MVA**, multivariate analysis; **Mw**, molecular weight; **NAM**,  
2 nicotinamide; **NMR**, Nuclear Magnetic Resonance; **nMSCs**, native mesenchymal stem cells; **NSCs**,  
3 Neural stem cells; **OECs**, Olfactory Ensheathing Cells; **P13K**, phosphoinositide 3-kinase; **PC**, phos-  
4 pchocholine; **PCA**, Principal component analysis; **PD**, Pompe disease; **PDH**, pyruvate dehydrogenase;  
5 **PKB**, protein kinase B; **PLC**, poly(DL-lactide- $\epsilon$ -caprolactone); **PLs**, phospholipids; **PLS-DA**, Partial-  
6 least squares discriminant analysis; **PPP**, pentose phosphate pathway; **PSCs**, pluripotent stem cells;  
7 **PTCs**, phosphatidylcholines; **PTEs**, phosphatidylethanolamines; **PTGs**, phosphatidylglycerols;  
8 **PUFA**, polyunsaturated fatty acid; **ROCK**, Rho kinase inhibitor; **SC**, stem cell; **SCRM**, single-cell  
9 Raman microspectroscopy; **SMs**, sphingomyelins; **SR-FTIR**, synchrotron radiation-based Fourier  
10 transform infrared; **SSCs**, spermatogonial stem cells; **SVZ**, subventricular zone; **TAG**, triacylglycer-  
11 ols; **TCA**, tricarboxylic acid; **TRPV**, transient receptor potential vallanoid sub-family 1; **UCMSC**,  
12 Umbilical Cord-Derived Mesenchymal Stem Cell; **VOCs**, volatile organic compounds; **YAP**, Yes-  
13 associated protein.

14

## 1 **1. Introduction**

2 Metabolomics has been increasingly employed within systems biology approaches to deepen the  
3 knowledge on stem cell (SC) characteristics and function. Compared to other omics, such as genomics  
4 or proteomics, metabolomics has more recently begun to be preferable applied in SC research [1] as it  
5 reflects not only upstream cell characteristics (genes, RNA, proteins), but also serves as a highly sensi-  
6 tive probe to external stimuli and SCs cross talk within their particular niche. This review provides an  
7 updated account of the main advances in metabolomics in SC research, with particular emphasis (alt-  
8 hough not exclusively) on findings reported in the last 5 years. This text begins with an introduction to  
9 the definition of metabolomics, the general analytical and statistical approaches usually involved, and  
10 the adaptation of typical metabolomics protocols (often applied to human biofluids/tissues) to the  
11 analysis of cells. An schematic brief account of SC metabolomic studies carried out to date will fol-  
12 low, while the main body of the review will focus on the metabolomic studies of the function and be-  
13 haviour of different SC types, in different conditions. Metabolomic studies of SCs in cancer research  
14 were considered out of the scope of this review due to their specificity/extension (relevant information  
15 may be found elsewhere [2]), as were the wide range of studies of the impact of drugs, contaminants,  
16 immunomodulators and other agents on SC metabolism.

17

## 18 **2. Cell metabolomics and brief overview of applications in stem cell research**

19 Metabolomics consists of the comprehensive analysis of large numbers of low molecular weight en-  
20 dogenous molecules, or metabolites, in biological systems, using advanced profiling analytical tech-  
21 niques, typically Nuclear Magnetic Resonance (NMR) spectroscopy or Mass Spectrometry (MS),  
22 combined with multivariate statistical analysis (MVA) [3]. Metabolomics aims at determining fluctua-  
23 tions on metabolite levels, in biological matrixes (biofluids, tissues or cells), usually to probe the  
24 origin/impact of diseases or other perturbations (*e.g.*, therapy, diet, contaminants) on a living organism.  
25 Deviant metabolic features may pave the way to further understand organism response and unveil metabol-  
26 ic biomarkers of biological status. Metabolomics can either follow an untargeted approach, usually em-  
27 ploying the more holistic NMR technique, or target a particular family of compounds for which prior  
28 knowledge on their relevance exists. Targeted metabolomics often benefits from the higher sensitivity  
29 of MS methodologies (<picomolar, compared to sub-millimolar in NMR), usually in tandem with a  
30 previous separation step, while untargeted NMR strategies offer higher reproducibility, non-  
31 destructiveness, and simple sample preparation (associated to automation and high-throughput character-  
32 istics well suited to omic approaches). Both analytical strategies are complementary and provide large  
33 amounts of data, which require MVA (either unsupervised, *e.g.* principal component analysis, PCA, or  
34 supervised, *e.g.* partial-least squares discriminant analysis, PLS-DA) to extract relevant and robust in-  
35 formation on metabolic response. Less often, targeted metabolomics may also involve i) isotopic tracing  
36 protocols that highlight particular metabolic pathways and help unambiguous conclusions to be drawn on  
37 their regulation, as shown for SCs either using NMR or MS [4, 5] and ii) single-cell localized lipid anal-  
38 ysis, through MS or vibrational spectroscopy in tandem with microscopy [1, 6], both subjects also men-  
39 tioned in this review. Although the main use of metabolomics has involved human biofluids/tissues [3],

1 adequate protocols for cell harvesting and metabolism quenching have been developed for metabolomics  
2 [7], usually for analysis of cell extracts or endometabolome (*fingerprinting*) and/or of cell media or exo-  
3 metabolome, including cell secretome (*footprinting*). NMR offers the additional possibility to directly ana-  
4 lyze cell pellets, using high-resolution-magic-angle-spinning (HRMAS) and, thus, minimize extraction-  
5 related metabolite alterations or loss, while assessing cell characteristics near to their native status [8]. A  
6 typical workflow for cell metabolomics (Fig. 1) usually begins with the challenging need to harvest large  
7 enough cell numbers and perform several independent assays, to enable a dataset that allows suitable statis-  
8 tical validation and unveil new metabolic information.

9 In its application to SCs, metabolomics has addressed many aspects of these cells' properties and func-  
10 tion. SCs are unspecialized (or undifferentiated) cells that can reproduce extensively (self-renewal) and  
11 have the ability to differentiate into specialized cells (potency) [9, 10]. These cells are usually classified  
12 with basis on: a) source - embryonic SCs (ESC, obtained from blastocysts in their early stages of de-  
13 velopment), and adult SCs (further classified depending on their location and/or type of lineages they  
14 can originate), and b) differentiation potency – totipotent (can give rise to embryonic and extraembry-  
15 onic cell types), pluripotent (capable of producing any type of adult cell), multipotent (with multi-  
16 lineage potential) and unipotent (able to differentiate into one lineage alone). Within the scientific com-  
17 munity, a rising and sustained interest in SC metabolomics has become clear over recent years (Fig. 2A),  
18 this account not including metabolic studies which measure only specific metabolites (and which thus do  
19 not qualify as metabolomic). Such studies have included untargeted and targeted strategies, with MS ap-  
20 proaches predominating, compared to NMR. Most studies have addressed changes in SC metabolic profile  
21 due to different origins, or donors, or differentiation conditions, followed by studies of varying culture con-  
22 ditions (*e.g.* hypoxia or varying media composition). Some reports have addressed cellular aging, senes-  
23 cence or autophagy, or helped to support disease models (Fig. 2B). Mesenchymal SCs (MSC, multipotent  
24 adult SCs, isolated from different tissues, and which mainly differentiate into mesenchymal lineages,  
25 *e.g.* fat, bone and cartilage cells, although differentiation into other lineages is also possible) have been the  
26 target of most reports in all contexts, except disease models, whereas a consistent interest has become clear  
27 in the metabolism of pluripotent SCs (PSCs, that include embryonic SCs, or ESCs, and induced PSCs,  
28 or iPSCs, which are reprogrammed directly from a somatic cell through co-expression of defined plu-  
29 ripotency factors). Neural SCs (NSCs, multipotent adult SCs that give rise to neuronal and glial cells)  
30 have been the subject of fewer reports, along with other SCs (Fig. 2B). A few recent review papers (Table  
31 1) have highlighted the prospective value of metabolomics in SC research, having discussed complementa-  
32 rity of NMR/MS metabolomics in MSC analysis and its potential compared to other omics [11], recogniz-  
33 ing MS-based lipidomics as important to characterize adipocytes [12] and study lipid-mediated SC regula-  
34 tion [13], and including a critical global account of existing methods [1] while drawing attention to the need  
35 to carry out, not only typical cell metabolomic studies, but also metabolic flux analysis (or isotope tracing)  
36 and single-cell metabolomics (with in tandem microscopy).

37  
38  
39

### 1 3. Metabolomics of mesenchymal stem cells (MSCs)

#### 2 3.1. Metabolic profile variability between tissue sources and donors

3 MSCs have been widely chosen as promising treatment options for various injuries and diseases,  
4 many studies having clearly established that their proliferation, differentiation, and immunological  
5 characteristics may differ significantly between source tissue types and donors. A global lipid profiling  
6 MS study of cell extracts showed that mouse ear MSCs, 3T3-L1 white preadipocytes, and BAT-C1  
7 brown preadipocytes differed significantly in lipid composition [14]. A more recent MS-based metabo-  
8 lomics study [15] compared human SCs derived from bone marrow (hBMMSCs), adipose tissue  
9 (hAMSCs), periodontal ligaments (hPDLSCs) and salivary glands (hSGSCs), harvested from differ-  
10 ent donors. The levels of endogenous metabolites were significantly dependent on tissue type and  
11 MVA revealed significant changes in the levels of lysophosphatidylcholines (lower in hPDLSCs and  
12 hSGSCs) and lysophosphatidylethanolamines (higher in hPDLSCs and hSGSCs), such compounds  
13 having been suggested as potential biomarkers of source tissue, with possible relation to different dif-  
14 ferentiation capacities.

15 Increasing interest has been noted on metabolomics of MSC secretomes, which can comprise both  
16 soluble metabolites and extracellular vesicles important to cellular function. Cell supernatants ana-  
17 lysed by liquid chromatography (LC)-MS metabolomics were observed to differ between hBMMSCs  
18 and hAMSCs, and suggested to relate to different efficacies of these cells in atherosclerosis therapies  
19 [16]. Indeed, exometabolome analysis revealed different impacts on the metabolisms of linoleic acid  
20 (LA), sugars and their derivatives (*e.g.* galactose, amino sugars and nucleotide sugars), amino acids  
21 (proline, glycine serine) and retinol. The authors noted, however, that inter-donor variability might  
22 contribute to the observed metabolic differences. More recently [17], it was reported that mouse AM-  
23 SCs harvested from subcutaneous adipose tissue and visceral adipose tissue (related to the onset of  
24 metabolic diseases) exhibited complex  $^1\text{H}$  NMR spectra (Fig. 3) and different exometabolome charac-  
25 teristics (as observed through MVA scores and loadings analysis, Fig. 4a,b), as well as distinct prolif-  
26 eration/differentiation potentials. Results showed that, although both cell types presented high secre-  
27 tion of lactate and citrate (alterations in glycolysis and mitochondrial metabolism, namely tricarbox-  
28 ylic acid, TCA, cycle), visceral AMSCs used mostly glycolysis. By changing culture media composi-  
29 tion, distinct sensitivity to glutamine availability seemed to distinguish the two cell groups, along with  
30 different glutaminolysis roles in pyruvate metabolism. The distinct patterns of pyruvate assimilation  
31 were suggested to account for the lower ability of visceral AMSCs to differentiate into adipocytes and  
32 osteoblasts (Fig. 4c), unveiling the importance of metabolic mechanisms as potential discriminators  
33 between AMSCs from different depots [17]. The importance of exometabolome was again highlighted  
34 in a comparative study of hMSCs isolated either from umbilical cord stroma (Wharton jelly, UCM-  
35 SCs) or from dental pulp (DPSCs) [18], both less invasive and ethically accepted sources of MSCs for  
36 therapy. The study presented a complete account of NMR secretome profiling and measurement of an  
37 extensive set of bioactive factors, in relation to cell characteristics and differentiation performance (in  
38 osteogenesis, adipogenesis and chondrogenesis). Secretome composition, characterised by  $^1\text{H}$  NMR,  
39 was seen to vary in relation to levels of pyruvate, lactate, alanine and other metabolites, mostly related

1 to energy metabolism. The authors indicated, however, that overall profiles were similar for the two  
2 cell types over the conditioning period, whereas more significant changes were noted in secreted bio-  
3 active factors (although not impacting significantly on cell proliferation, migration, or tube formation  
4 capacity).

5 In relation to donor characteristics, the impact of donor obesity on hAMSCs endo- and exomet-  
6 abolomes was measured by MS metabolomics (LC-MS, gas chromatography(GC)-MS and capillary  
7 electrophoresis(CE)-MS) to investigate obesity implications on AMSCs stemness capacity [19]. Re-  
8 sults unveiled increased secretion and intracellular accumulation of metabolites associated with gly-  
9 colysis, TCA cycle, pentose phosphate pathway (PPP) and polyol pathway in obesity-derived hAM-  
10 SCs compared to controls, in tandem with decreased proliferation, migration and differentiation abili-  
11 ties. In the same study, murine AMSCs also revealed significant changes in obese animals, particularly  
12 related to lipid and amino acid catabolism, however such features differed from those obtained for  
13 hAMSCs, highlighting that extrapolation of animal data to humans must be handled with care. Other  
14 authors have proposed the use of iPSCs-derived MSCs (iMSCs) to circumvent inter-donor variability  
15 [20]. The study compared native MSCs (nMSCs) with their corresponding iMSCs, for two different  
16 donors and using two different protocols. Cell endometabolome was analyzed by GC-MS, in tandem  
17 with other characteristics comprising differentiation capability, transcriptome, immunomodulatory  
18 potential and response to the proinflammatory interferon gamma (IFN- $\gamma$ ) cytokine. Unsupervised  
19 MVA of GC-MS data indicated enhanced metabolic activity in nMSCs and in some iMSCs, depending  
20 on the differentiation protocol employed, which also impacted importantly on immunomodulatory  
21 potential, plasticity and proliferation capacities [20]. It was concluded that, although the two differen-  
22 tiation protocols produced iMSCs similar to nMSCs, the few differences noted indicated the need of  
23 adequate protocol definition according to the desired clinical end use.

## 24 25 **3.2. Differentiation**

### 26 **3.2.1. Adipogenesis**

27 An initial report compared the  $^1\text{H}$  HRMAS NMR spectra (cell pellets) of mouse BMM-  
28 SCs before and after adipogenic differentiation [21], with a view to translating results (de-  
29 creased levels of choline, creatine, glutamate, *m*-inositol, and increase in fatty acids, FAs) into  
30 non-invasive *in vivo* magnetic resonance imaging (MRI) measurements. Most subsequent  
31 studies targeted lipids, often for comparison of differentiated MSCs with adult adipose tissue  
32 cells. NMR of hUCMSCs extracts [22] recognized the need for high cell numbers (*ca.*  $7 \times 10^6$ )  
33 and indicated increased methionine and FAs levels (and non-detectable creatine) as character-  
34 istic of adipogenesis. Subsequent reports employed MS metabolomics, with hBMMSC lipid  
35 extracts unveiling changes in free FAs throughout adipogenesis [23, 24]. MSC-differentiated  
36 preadipocytes (days 5-7) and adipocytes (day 21) lacked specific elongases (possibly hinder-  
37 ing endogenous polyunsaturated FA, PUFA, synthesis) and differed from primary adipocytes  
38 in decreased levels of LA,  $\alpha$ -linolenic acid (ALA) and arachidonic acid (AA); and increased



1 docosahexaenoic acid (DHA). The absence of essential FAs in adipogenic media (suggesting  
2 them as potential interesting supplements) was related to the MSCs inability to differentiate  
3 into fully functional adipocytes. GC-MS lipid analysis of rat BMMSCs, in tandem with func-  
4 tional studies, confirmed distinct lipid compositions for BMMSC-derived and native adipo-  
5 cytes, consistently with intra-cellular accumulation of autophagic vesicles rather than lipid  
6 droplets in the former. A lipidomics MS study [14] of MSCs extracts of different tissue types  
7 compared undifferentiated cells with derived adipocytes, and with mouse native adipose tis-  
8 sue cells (perirenal and inguinal white tissues, and interscapular brown adipose tissue). Sub-  
9 stantial differences were noted in the levels of triacyl- and diacylglycerols (TAG and DAG),  
10 sphingomyelins (SM), glycerophospholipids, cardiolipin and hexosylceramides, results sug-  
11 gesting new lipid biomarkers for tissue-specific adipogenic processes.

12 More recently, adipogenic differentiation of hAMSCs was followed through GC-MS of volatile  
13 organic compounds (VOCs) in the headspace of cell cultures [25]. Adipogenesis was accompanied by  
14 changes in some VOCs, including acetaldehyde (related to mitochondrial pyruvate decarboxylation)  
15 and other compounds possibly related to increased oxidation processes [25]. The same type of SC was  
16 used to reconstruct a 3D adipose tissue model for comparison with native adipose tissue, comparing  
17 adipogenesis differentiation characteristics, as well as TAGs (main constituents of intracellular lipid  
18 droplets) and phospholipids (PLs) profiles, measured by GC-MS [26]. MVA of GC-MS data and In-  
19 genuity pathway analysis assessed differential pathways between native and reconstructed adipose  
20 tissue, determined by distinct gene expression features. Genes regulating lipid metabolism were down-  
21 regulated in reconstructed tissue, possibly relating to the noted insufficient levels of essential FAs.  
22 Interestingly, culture medium supplementation, for instance with LA, was seen to alter end-point lipid  
23 profile in reconstructed tissue, emphasizing the possibility of media supplementation to specifically  
24 modulate PL profile. Combination of omics (metabolomics of both non-lipid metabolites and of lipids,  
25 or lipidomics, and proteomics) to follow hAMSC adipogenesis involved a LC-MS-based strategy [27]  
26 that unveiled reprogramming of more than 100 metabolic pathways in differentiated cells, revealing  
27 TAGs, gangliosides, and carnitine as important players in adipogenesis, along with down regulation of  
28 specific nucleotide derivatives and amino acids. The influence of different MSCs sources (rabbit adi-  
29 pose tissue or skeletal muscle) on lipidome evolution upon adipogenesis (compared to osteogenesis, as  
30 the two processes are found to often compete), assessed by MS of lipid extracts [28], showed that dif-  
31 ferentiation triggered changes in lipid composition, which however led to end lipid profiles that did  
32 not significantly depend on the original source tissue.

33 Although to a much lesser extent, vibrational spectroscopy has also been used in the study of  
34 MSCs adipogenesis. Following an initial Raman spectroscopy study of hAMSCs [29] that showed,  
35 through PCA of cell culture spectra, changes in a lipid band at  $1438\text{ cm}^{-1}$  during adipogenesis, a syn-  
36 chrotron radiation-based Fourier transform infrared (SR-FTIR) microspectroscopic study of single  
37 hMSCs cells [30], as a function of time, reported changes in lipid structure and nucleic acids, as early

1 as days 1-3 of the differentiation process. This report revealed other important early-stage changes in  
2 cell components, which may determine further changes in low molecular weight ( $M_w$ ) intracellular  
3 compounds. SR-FTIR was further applied to investigate the regulating role of the Yes-associated pro-  
4 tein (YAP) in hMSC differentiation into fat and bone, having reported unique metabolic fingerprints  
5 for cells with different YAP expression levels [31].

### 7 **3.2.2. Osteogenesis**

8 In relation to 2D MSC cultures, one study monitored dexamethasone (Dex)-induced osteogenesis  
9 of mouse BMMSCs using LC-MS metabolomics of culture media [32], having registered a clear met-  
10 abolic trajectory over time (Fig. 5). MSCs conditioned media exhibited increased levels of metabolites  
11 possibly related to cell proliferation, some of which (*e.g.* citrate, *cis*-aconitate, 2-oxoglutarate, succin-  
12 ate, glycerol, orthophosphate) were suggested as potential biomarkers of osteogenesis. Another report  
13 [33] considered hUCMSCs cultures and analysed cell extracts by GC-MS, during osteogenesis in-  
14 duced either by Dex or bone morphogenetic protein 2 (BMP-2). Results showed that hUCMSCs go  
15 through various metabolic stages before reaching their final, treatment-dependent, metabolic pheno-  
16 type. Dex induced a global metabolic hyperactivity at day 7 (increased levels of glutamine, cholester-  
17 ol, one-carbon metabolism intermediates, PLs, and glycerolipid precursors), subsequently reduced at  
18 day 14, and continuing to decrease until day 21 (low levels of TCA cycle, glycolysis, and glutaminol-  
19 ysis intermediates). BMP-2-stimulated cells exhibited less metabolite variations and a 7 day-delay,  
20 reflecting lower osteogenic efficiency. The end metabolic profile of Dex-treated cells was similar to  
21 that of primary osteoblasts, although showing higher levels of glucose, lactate, glutamine, lipid precur-  
22 sors, and TCA cycle intermediates. Some research has been directed to the use of giant plasma mem-  
23 brane vesicles (GPMVs) and MS metabolomics has shown that hBMMSC differentiation leads to line-  
24 age-specific lipidomic remodelling in the plasma membrane, resulting in unique membrane pheno-  
25 types for osteoblasts or adipocytes [34]. Following supplementation with DHA (a  $\omega$ -3 FA), an osteo-  
26 blastic membrane phenotype was promoted, possibly by up-regulating Akt (or protein kinase B, PKB)  
27 and unveiling a potential mechanism for dietary lipids promotion of and bone. Later, it has been sug-  
28 gested that GPMVs generated by osteoblasts [35] can direct osteogenic differentiation of hMSCs, pos-  
29 sibly depending on size, complexity and lipid composition, as viewed by NMR of GPMV extracts.  
30 More recently, the role of YAP in regulating the adipo-osteogenic balance of hUCMSCs was investi-  
31 gated [31]. FTIR microspectroscopy was used to track structural changes of nucleic acids, proteins,  
32 and lipids in differentiated cells after manipulation of the YAP expression level. It was clear that YAP  
33 promoted osteogenesis (even within an adipogenic medium), whereas the absence of YAP induced  
34 adipogenesis. Notably, YAP-targeted differentiated cells and non-manipulated controls all displayed  
35 unique metabolic fingerprints. In addition, the role of natural products in SC differentiation has trig-  
36 gered some interest and the effect of astaxanthin (AST), a carotenoid pigment, on osteogenic differen-  
37 tiation of rat BMMSCs endometabolome was studied by LC-MS metabolomics [36]. Depending on  
38 the dose, AST was observed to impact on the levels of amino acids, organic acids and other com-  
39 pounds, and metabolic pathway enrichment analysis unveiled that AST mainly regulated phenylalala-

1 nine metabolism; phenylalanine, tyrosine, and tryptophan biosynthesis; and pantothenate and coen-  
2 zyme A (CoA) biosynthesis during the process of osteogenic differentiation.

3 Regarding MSCs osteogenesis, many studies have explored different 2D nanostructures and  
4 2D/3D cell culture hydrogel-based environments. The physical properties of biomaterials alone have  
5 been observed to induce osteogenesis, for example, through nanotopography or mechanical stimuli  
6 (mechanotransduction), without the need for chemical or biological differentiation inductors. For in-  
7 stance, NSQ50 surfaces (engineered with 120 nm diameter dots disordered by a 50 nm offset in x/y  
8 axes) triggered osteogenesis, contrary to more tightly controlled dot arrangement surfaces (named  
9 SQ), which prolonged multipotency and led to modest differentiation degree [37]. With basis on MS  
10 data and metabolic pathway analysis, together with small RNA microarray analysis, among other  
11 measurements, the authors proposed that the observed increased levels of unsaturated metabolites in  
12 undifferentiated MSCs (compared to cells exposed to NSQ50) seemed related to mediation of differ-  
13 entiation through redox status regulation and activation of oxidative pathways. Furthermore, it was  
14 suggested that SQ surfaces mimic small adhesion sites in the hBMMSCs niche, whereas in NSQ50,  
15 MSCs have significantly larger adhesion complexes and intracellular tension that induce osteogenesis  
16 [37]. Adhesion blockage (with integrin antibodies) on SQ surfaces led to up-regulation of amino acid,  
17 lipid, nucleotide and carbohydrate metabolism, as active differentiation was initiated and, in the same  
18 report, LC-MS of cell fingerprints was recognized as an almost instant indicator of MSCs phenotype  
19 (compared to transcriptomics or proteomics) with high sensitivity to nanotopography-induced metabo-  
20 lite reorganizations. Other work revealed a possible association of lipoate, sphingosine, and several  
21 amino acids with the osteogenesis of hBMMSCs cultured on titania planar or nanostructured surfaces  
22 [38]. MSC osteogenic potential and associated intracellular LC-MS metabolic profiles were also eval-  
23 uated on polycaprolactone surfaces patterned with bacterial inclusion bodies (IB) [39], used to vary  
24 surface topography, stiffness and wettability. A general metabolic up regulation trend was noted, with  
25 increased levels of carbohydrates, nucleotides, lipids, and amino acids. In addition, regulation of cell  
26 adhesion for the study of MSCs growth and differentiation was carried out by using enzyme-cleavable  
27 nanoscale surfaces [40]. A noted switch from low to high adhesion conditions led to significant  
28 metabolome changes, as viewed by LC-MS of cell extracts. High adhesion that promoted osteogenesis  
29 led to changes in pathways involved in energy, growth, protein, and skeletal development, whereas  
30 reduced adhesion was suggested to possibly result in adipogenesis. A very recent report [41] has also  
31 shown that microparticles with different architectural features induce distinct osteogenic behaviour of  
32 hBMMSCs, accompanied by significant change in the LC-MS metabolic profile of the cells exomet-  
33 abolome. Furthermore, the suitability of oxidized alginate (alginate di-aldehyde, ADA) functionalized  
34 with glycine-histidine-lysine (GHK) peptide, was compared to gelatin-based control hydrogels for  
35 seeding and enhancing hUCMSCs osteogenic differentiation [42]. As revealed by MVA of GC-MS  
36 metabolomics data, hUCMSCs in ADA-GHK hydrogels unveiled metabolic profiles that grouped  
37 close to those of primary osteoblasts (although retaining lower levels of lipids, lipid precursors choles-  
38 terol and *m*-inositol, and some amino acids: glutamine, threonine, aspartate and tyrosine), confirming  
39 improved osteogenic potential. Osteogenesis was accompanied by reduced activity of glycolysis, TCA

1 cycle, glutaminolysis and urea cycle, following a transition from a glycolytic phenotype in undifferen-  
2 tiated MSCs to significant energy-producing oxidative phosphorylation in differentiated cells. The  
3 authors suggested that GHK action in MSCs may relate to integrin  $\beta$ 1 and mediated by integrin linked  
4 kinase (ILK). Furthermore, the interaction between hAMSCs and a 3D nanocomposite scaffold com-  
5 posed of polyurethane, nano-hydroxyapatite, and decellularized bone particles was assessed through  
6 variations in both transcriptional and metabolite domains, the latter measured by LC-MS [43]. hAM-  
7 SCs seeded on material scaffolds were compared to standard 2D cell cultures and several metabolites  
8 were specifically related to osteogenesis supported by the 3D scaffold, which contributed to an intri-  
9 cate cellular environment, promoting cell attachment and subsequent osteogenesis.

10 Interestingly, a nanovibrational bioreactor of hBM MSCs in 3D collagen gels was also observed to  
11 stimulate metabolic profiles characteristic of osteogenesis (upregulated lipid and carbohydrate path-  
12 ways), linked to signalling mechanisms *e.g.* associated to adhesion and cytoskeletal tension, while  
13 leading to mineralized 3D tissue [44]. The role of mechanoresponsive channels in the osteogenic pro-  
14 cess was investigated, and transient receptor potential vullanoid sub-family 1 (TRPV) channels were  
15 proposed to play an important role in the activation of  $\beta$ -catenin signalling. The use of a nanovibra-  
16 tional bioreactor that converts hBM MSCs into bone-forming osteoblasts was further investigated as to  
17 vibrational amplitude conditions and induced cell mechanisms, importantly bringing together LC-MS  
18 metabolomics, gene and protein adaptations, in a full interdisciplinary study (Fig. 6) [45]. Increased  
19 vibrational amplitudes led to changes, not only in adhesion and ion channel expression, but also in the  
20 activation of energetic metabolic pathways, in turn related to low levels of reactive oxygen species  
21 (ROS) and inflammation, characteristics resembling those of natural bone-healing processes.

### 23 3.2.3. Differentiation into other lineages

24 NMR of the exometabolome of hUBMSCs during neuroglial differentiation on poly(DL-  
25 lactide- $\epsilon$ -caprolactone) (PLC) membranes [46] showed evidence of a metabolic switch from glycoly-  
26 sis-dependent expansion of undifferentiated cells to an oxidative metabolism characteristic of differen-  
27 tiated cells. The presence of more alanine than lactate in the media of neuroglial-like cells was associ-  
28 ated with a reduced redox cytosolic state, which may indicate an important role of oxidative stress  
29 during the neuroglial differentiation of hUBMSCs. In tandem with *in vivo* testing of both undifferenti-  
30 ated and differentiated hUBMSCs, the authors have stated the promising potential of hUBMSCs, de-  
31 livered through PLC membranes, for treating trauma to sensory nerves. Two metabolomic studies  
32 [47][48] have monitored the dynamic metabolism of hBM MSCs during chondrogenesis in 3D cultures.  
33 NMR analysis of cell-containing alginate beads suspensions [47] identified several metabolites as  
34 potential markers of chondrogenesis: increased FAs, decreased alanine and leucine, and increased  
35 glutamate and GABA. Chondrogenesis was also studied by MS imaging to determine lipids spatial  
36 distribution in hBM MSCs 3D micromasses, during the first steps of chondrogenic differentiation [48].  
37 Over time, there were decreases in phosphocholine (PC), phosphatidylcholines (PTCs) and SMs, and  
38 increases of ceramides (products of SM metabolism), inositol- and ethanolamine-derived PLs.

### 3.3. Culture conditions

Several beneficial roles of hypoxia on SC biology have been recognized, including maintenance of undifferentiated status, cell proliferation rate enhancement, senescence inhibition, as well as on directing cell differentiation ability [49]. hMSCs under low oxygen tension were shown, by GC-MS and isotopic tracing of  $^{13}\text{C}$ -glucose [50], to undergo increased glucose consumption, reduced pyruvate dehydrogenase (PDH) activity, and some extent of oxidative-phosphorylation, with oxygen tension having more subtle effects on hMSCs, compared to the differentiated cells (osteoblasts). Lipids have been revealed to play unexpected important roles in chondrogenesis, when carried out in hBMMSCs/chondrocytes co-cultures [51], where MS and MVA indicated that, under low oxygen tension, lipids decrease (in particular, cholesterol) seemed to be associated to improved extracellular matrix (ECM) deposition under hypoxia. On their own, hBMMSCs responded to hypoxia in a different way, as shown by up-regulation of TAGs, FAs and DAG, the latter suggested to affect MSC angiogenic potential [52]. Using chemical isotope labelling LC-MS metabolomics, several endo- and exometabolites metabolites of human placenta-derived MSCs (hPMSCs) were also suggested as potential biomarkers of hypoxia, indicating a perturbation in arginine and proline metabolism, pantothenate and CoA biosynthesis, and alanine, aspartate, glutamate metabolisms [53]. More recently, MSCs exposed to hypoxia and serum deprivation displayed decreased expression of numerous lipid membrane components and significant alterations in glycolysis and TCA cycle intermediates, as viewed by GC-MS and LC-MS metabolomics, suggesting a conversion from aerobic respiration to glycolytic metabolism [54]. In the same study, exosomes (nanovesicles that mediate intercellular signalling) derived from these MSCs were shown to be packed with metabolites linked to the biosynthesis of amino acids, carbohydrates and nucleosides, including metabolites associated with anti-inflammatory and immunoregulatory functions. Hypoxia mimetic agents may be employed to avoid hypoxic culturing, which is difficult and expensive to carry out, and the effectiveness of desferrioxamine (DFO) in that role was investigated by GC-MS and LC-MS metabolomics of hBMMSCs to compared hypoxic and DFO-induced conditions [55]. The observed similar metabolic changes noted (except for purines, pyrimidines, and TCA cycle metabolites) led the authors to suggest low-concentration DFO as a potential substitute for hypoxic culturing.

Other culture conditions have been studied by metabolomics, for instance,  $^1\text{H}$  NMR was used to compare unconditioned commercial and supplemented media (without cell contact) and during hUCMSCs expansion (conditioned media, considered as a possible alternative to hUCMSCs transplantation procedures) (Fig. 7) [56]. Conditioned media exhibited high concentrations of metabolites and soluble factors with proliferative, chemotactic, and immunomodulatory properties and provided valuable information on hMSCs metabolism *in vitro*. In addition, the MS metabolic profiles of hMSCs expanded under different cellular densities [57] unveiled several differences in glycolysis, oxidative phosphorylation, glutamine metabolism, and in the role of the pentose phosphate pathway, for maintaining cellular redox state. Furthermore, a recent study regarded the possible effect of low-intensity pulsed ultrasound (LIPUS) in promoting the proliferation of hASCs [58], as shown by LC-MS metab-

1 olomics and transcriptome experiments, which identified changes in 30 metabolites and in 27 genes,  
2 respectively.

### 3 4 **3.4. Aging, senescence, and autophagy**

5       Regardless of their source, MSCs aging may affect their replicative potential, immunomodulatory  
6 properties and differentiation capacity, thus some metabolomic studies have explored *in vitro* aging (or  
7 replicative senescence). In an initial work, proteomics was combined with NMR metabolomics to in-  
8 vestigate the changes in H<sub>2</sub>O<sub>2</sub>-induced premature senescent hMSCs [59], showing increases in leucine  
9 and choline, and decreased in glycine and proline, probably as the result of higher H<sub>2</sub>O<sub>2</sub>-induced ROS  
10 levels. Subsequently, integration of lipidomics (through MS) with transcriptomics unveiled changes in  
11 lipid metabolism during *in vitro* aging, namely up-regulation of the majority of glycerophospholipids  
12 (PTCs, phosphatidylethanolamines (PTEs), and phosphatidylglycerols (PTGs)), sphingolipids (SMs,  
13 ceramides, cerebroside, and gangliosides), and glycerolipids (DAG and some TAG) and down-  
14 regulation of a few glycerophospholipids and sphingoid bases [60]. These results suggested that aging-  
15 related lipid metabolism may play an important role in aberrant differentiations of hMSCs and might,  
16 to some extent, relate to an increased potential of adipogenic differentiation in aged BMSCs [60]. Fur-  
17 thermore, *in vitro* aging of hMSCs, as measured by GC-MS and LC-MS metabolomics, was suggested  
18 to involve a senescence-associated shift from oxidative metabolism (passages 2-5) to glycolytic path-  
19 ways (passage 11) [61]. Autophagy capacity is a requirement for stemness and differentiation capaci-  
20 ty, however it is known to decline with MSCs aging. This process was investigated for human placen-  
21 ta-derived hPMSCs through chemical isotope labelling LC-MS to target amine/phenol-containing and  
22 carboxylic acid-containing metabolites [62] and results showed a significant impact on argi-  
23 nine/proline metabolism,  $\beta$ -alanine metabolism and FA biosynthesis pathway.

## 24 25 **4. Metabolomics of pluripotent stem cells (iPSCs and ESCs)**

### 26 **4.1. Metabolic remodelling during pluripotency acquisition**

27       NMR footprinting and fingerprinting, in tandem with proteomics, was able to distinguish iP-  
28 SCs from parental fibroblasts, in terms of metabolite levels that indicated elevated glucose utilization  
29 and production of glycolytic end products [63]. The authors concluded that the energetic metabolism  
30 of somatic cells converts into a required glycolytic metabotype, to induce pluripotency. More recently,  
31 the metabolomic profiles of rat ESCs, iPSCs and embryonic fibroblasts (EFs), were compared using  
32 NMR and LC-MS of cell extracts, as well as NMR of the exometabolomes [64]. Results showed that  
33 EFs reprogramming into iPSCs involved significant changes in cell metabolic profiles, while those of  
34 ESCs and iPSCs were much less marked, comprising differences in the levels of adenosine, cysteic  
35 acid, glucose, glycerophosphoglycerol, guanosine, inositol phosphate, m-inositol, phosphoserine and  
36 xanthosine.

37       Besides the reports above, most studies of the metabolic signature and biological events in-  
38 volving PSCs have been carried out by MS metabolomics, to the best of our knowledge. Sphin-  
39 golipids, and particularly ceramides, have been analysed for the differentiation of mouse ESCs into

1 embryoid bodies (EBs) [65], using LC-MS for ceramide identification and transcriptomic profiling for  
2 mRNA measurements. Results indicated that conversion of mESCs to EBs is accompanied by changes  
3 in gene expression changes as well as in distribution for both sphingolipids and fatty acyl-CoAs. Other  
4 metabolomic studies reported that iPSCs exhibited a metabolic shift away from parental cells (and  
5 towards ESCs), displaying a clear conversion from somatic oxidative bioenergetics to glycolysis [63,  
6 66] and a dynamic remodelling of PLs [67], along with decreased levels of pyrimidine and purine nu-  
7 cleotides, Krebs cycle intermediates [66] and some amino acids [68]. Despite the metabolic similarity  
8 of iPSCs and ESCs, iPSCs were found to have lower levels of unsaturated FAs and higher levels of  
9 metabolites involved in the *S*-adenosyl methionine cycle, suggesting that iPSCs adapt to a more ESC-  
10 like state the longer they remain in culture [66]. Another study [68] reported other differences between  
11 iPSCs and ESCs, namely in terms of PTCs, PTEs, amino acids and polyamine biosynthesis intermedi-  
12 ates. Interestingly, partially reprogrammed cells were found to be characterized by an intermediate  
13 metabolic profile between those of fully reprogrammed iPSCs and their parental cells [69], as viewed  
14 by CE-MS metabolomics. The same technique was employed to help monitor iPSC quality through  
15 footprinting [70]. In the same year, a GC-MS metabolomics report addressed hPSCs response to Rho  
16 kinase inhibitor (ROCK), a serine-threonine kinase which helps maintaining growth and pluripotency  
17 [71]. Importantly, while gene expression and protein levels did not reveal any changes in the physiol-  
18 ogy of the cells, metabolomics revealed the fluctuating state of the metabolism, namely ROCK expo-  
19 sure leading to changes in glycolysis, glutaminolysis, the TCA cycle as well as the amino acid metabo-  
20 lism. Finally, the role of lipid metabolism has been revisited in a few recent studies, one of which has  
21 coupled CE-MS metabolomics with targeted proteomics to characterise the role of FA biosynthesis in  
22 the differentiation of hPSCs into hPSC-derived cardiomyocytes (hPSC-CMs) [72], demonstrating the  
23 importance of de novo FA synthesis for the survival of undifferentiated hPSCs and suggesting FA  
24 synthase inhibition as useful tool in regenerative medicine.

25

## 26 **4.2. Differentiation**

27 Untargeted MS metabolomics on mESCs differentiation [73] indicated that mESCs become en-  
28 riched in highly unsaturated metabolites (including  $\omega$ -6 and  $\omega$ -3 FAs, *e.g.* AA, eicosapentaenoic acid,  
29 DHA), and depleted in saturated free FAs and acyl-carnitines. Interestingly, supplementation with  
30 these depleted compounds enhanced neuronal and cardiomyocyte differentiation, respectively, where-  
31 as eicosanoid pathway inhibitors promoted pluripotency. MS metabolomics was also used, in tandem  
32 with transcriptomic analysis, to establish that, although vascular endothelial and smooth muscle cells  
33 were metabolically distinct from the parental hESCs, their metabolic profiles seemed to match those of  
34 primary differentiated cells [74].

35 Many differentiation studies of PSCs using metabolomics have addressed iPSC differentiation into  
36 hepatocytes, mainly measuring lipid moieties by typical MS metabolomics, as a means to understand  
37 diseases such as fatty liver disease, atherosclerosis or acute liver failure. When in tandem with gene or  
38 transcriptomic profiling, as well as other biochemical measurements, such work has identified path-  
39 ways involving polyunsaturated PLs and sphingolipids as important during differentiation, as well as

1 FAs, biliary acids and metabolites involved in glycolysis, TCA cycle, pentose phosphate shuttle and  
2 FA oxidation, as shown by a recent development of a microfluidic biochip strategy (coupling metabo-  
3 lomics and transcriptomics) to follow human iPSCs maturation into hepatocytes [75]. Still on an ana-  
4 lytical note, other incurrences into chip-MS compared to LC-MS [76], HRMAS NMR compared to  
5 cell extract analysis [77], and single-cell Raman microspectroscopy (SCRM) [78] have been reported,  
6 aiming at further consolidating metabolite profiles of PSC differentiation. Characterisation of PSCs  
7 differentiation into endothelial cells [79] and neurons [77, 78] have also made use of metabolomics.

### 8 9 **4.3. Culture conditions**

10 In terms of different culture conditions, a CE-MS metabolomic analysis, in tandem with isotopic  
11 tracing studies [80], investigated the impact of media composition on hPSCs and derived cardiomyo-  
12 cytes. Glycolysis and glutamine oxidation were shown to be important pathways for energy generation  
13 and general survival of hPSCs, suggesting media tailoring as a strategy to eliminate residual and po-  
14 tentially harmful undifferentiated SCs. Isotopic tracing and GC-MS metabolomics were also used [5],  
15 supporting the idea that media importantly influence the metabolic state of hPSCs, being able to de-  
16 termine the interplay between lipogenic behaviour and redox pathways, again confirming a key role  
17 played by glutamine. A subsequent report employed NMR metabolomics to establish that ESC plurip-  
18 otency seems to rely on the available relative levels of ascorbic acid and L-proline, the authors sug-  
19 gesting an important epigenetic role for those metabolites [81].

20 In a different context, the exometabolomes of iPSC-derived cardiomyocytes exposed to hypoxic  
21 conditions were compared with those of equivalent cells from non-human primates, using LC-MS  
22 metabolomics and transcriptomic analysis [82], with the aim of investigating treatment of myocardial  
23 infarction. The inter-species metabolic similarities and disparities in terms of hypoxia-changed path-  
24 ways were discussed. Furthermore, another recent and multidisciplinary report [83] coupled LC-MS  
25 metabolomics with transcriptomic analysis, as well as epigenetic regulators and specific protein mark-  
26 ers, demonstrates that the use of a stirred suspension bioreactor results in more effective maintenance  
27 of a hPSCs state of naïve pluripotent state, which may improve hPSC production for therapeutic appli-  
28 cations.

### 29 30 **4.4. Disease models**

31 An earlier untargeted LC-MS study of cell extracts and media addressed the function of the Hun-  
32 tington locus (*htt*) gene and associated mutations and encoded proteins by comparing the metabolic  
33 profiles of syngeneic mouse ESCs [84]. The deviant metabolite levels thus found indicated metabolic  
34 aberrations triggered by *htt* in mESCs, *e.g.*, involving failure of ATP production, activated glycolysis  
35 and ketogenesis, depletion of intracellular nucleotides and deviant purine metabolism. Such results  
36 suggested a relationship between *htt*, mitochondrial function and early embryonic lethality. Other ap-  
37 plications have used MS metabolomics to address Pompe disease (PD), a condition originated by an  
38 inborn deficiency in acid  $\alpha$ -glucosidase, which causes glycogen excess in lysosomes (mainly in skele-  
39 tal muscle and heart). The associated cellular metabolism was investigated in a PD model, through



1 LC-MS and CE-MS of cardiomyocytes differentiated from late-onset PD iPSCs, having shown that  
2 metabolites related to oxidative stress and mitochondrial dysfunction seem particularly important [85].  
3 When PD occurs in early infancy, the patients suffer from serious muscle weakness and heart failure  
4 and iPSCs obtained from patients with infantile-onset PD and differentiated into myocytes were char-  
5 acterized by CE-MS metabolomics, in tandem with transcriptomic analyses [86]. Detected metabolite  
6 changes could be related to disturbance of mTORC1 signaling, involving changes in energy status and  
7 mitochondrial oxidative function, which may become possible therapeutic targets in PD. In the same  
8 year, in order to help investigate the metabolic impact of a genetic variant pinpointed by Genome-  
9 Wide-Association-Studies (GWAS) related to cardiometabolic disease, iPSCs obtained by repro-  
10 gramming of peripheral blood cells were then differentiated into hepatocytes and adipocytes and MS  
11 metabolomics was performed on all three cell types, targeting lipid species and nucleotide/nucleoside  
12 phosphates [87], in tandem with transcriptomics. In particular, lipid accumulation was observed in  
13 differentiated hepatocytes, providing additional knowledge on the effects of GWAS variants related to  
14 metabolic disease. In addition, fibroblast-like synoviocyte (FLS) cells and iPSCs derived from patients  
15 suffering from rheumatoid arthritis and osteoarthritis were characterized as to their LC-MS metabo-  
16 lomic profiles [88] in search for metabolic biomarkers of such diseases. The metabolic profiles of pa-  
17 tients' FLSs and iPLS cells were clearly distinguished upon PLS-DA analysis, and nicotinamide  
18 (NAM) was found to impact importantly on the proliferation of rheumatoid arthritis iPSCs. The NAM  
19 inhibitor tannic acid was investigated as a possible therapy for those patients. More recently, Danon  
20 disease, a condition related to deficiency of a lysosome membrane protein, which also affects the mus-  
21 cle, heart among other manifestations, was investigated by a metabolomics and transcriptomics (as  
22 well as Raman and atomic force microscopy) approach to compare the metabolic profiles of patient-  
23 derived cardiac tissue with primary fibroblasts and human iPSCs differentiated into cardiomyocytes  
24 [6]. Both undifferentiated iPSCs and iPSC-derived cardiomyocytes were analyzed by LC-MS and  
25 isotopic tracing experiments, results having unveiled the importance of glycolysis and tryptophan me-  
26 tabolism, among other characteristics, in determining loss of cardiac biomechanical competence and,  
27 hence, Danon disease progression.

28

## 29 **5. Metabolomics of neural stem cells (NSCs)**

### 30 **5.1. Differentiation**

31 As noted earlier, NSCs have been studied through metabolomics to a much lower extent, com-  
32 pared to MSCs and PSCs. One study has employed NMR and MVA [89] to unveil metabolic distin-  
33 guishing features between phenotypically similar SCs, namely rodent fetal, postnatal and adult NSCs  
34 (harvested from the subventricular zone (SVZ)) and Olfactory Ensheathing Cells (OECs, obtained  
35 from the olfactory bulb). Specific metabolite levels were observed to significantly vary both between  
36 NSCs and OECs, and between NSCs of different ages, with the results presenting potential usefulness  
37 in monitoring SC properties in different environments or in pathological conditions (*e.g.*, ageing and  
38 neurodegeneration). A second recent report was based on GC-MS and direct infusion (DI)-MS [90] to  
39 analyze both the polar and lipid metabolomes of rat NSCs (which proliferate in the presence of growth

1 factors) and differentiated cells (DCs, neurons and glia, in the absence of growth factors). Markedly  
2 distinct metabolic profiles were noted between NSCs and DCs, involving six lipids, together with cre-  
3 atinine, lactate, lysine, glutamine, glycine and pyroglutamate, such knowledge potentially aiding in the  
4 classification of NSCs and DCs in therapeutics of neurological disorders.

## 5 6 **5.2. Culture conditions**

7 As NSCs display tissue trophic and immune modulatory therapeutic roles in central nervous  
8 system (CNS) disorders, after transplantation, and it has been suggested that inflammatory cytokines  
9 may lead to metabolic reprogramming of NSCs to help regulate their immune modulatory effects [91].  
10 Mouse NSCs harvested from the SVZ of the animals were analysed by GC-MS and LC-MS cell fin-  
11 gerprinting and footprinting (in tandem with other measurements), upon exposure to specific inflam-  
12 matory cytokines. NSC incubation with <sup>13</sup>C-labeled arginine also helped tracking arginine and its  
13 downstream metabolites, by LC-MS. Results demonstrating the powerful hypotheses-generating abil-  
14 ity of metabolomics to help understand how SC-mediated actions of tissue regeneration are affected by  
15 local inflammation effects. Notably, arginase signalling was unveiled as important in the communica-  
16 tion between NSCs and the immune system. More recently, untargeted LC-MS metabolomics and  
17 pathway analysis supported a more global study of protein and metabolite changes in NSCs, in re-  
18 sponse to the IFN- $\gamma$  cytokine, either in solution or immobilized in a biomimetic hydrogel [92]. The  
19 aim of IFN- $\gamma$  immobilization was to provide conditions for prolonged NSCs neurogenesis to achieve  
20 more efficient therapeutic results in treating CNS injury. Both soluble and immobilized IFN-  
21  $\gamma$  triggered changes in energy, lipid, and amino acid metabolisms, with the former impacting more  
22 significantly on NSC metabolome. Along a similar context, mouse NSCs have been cultured in a 3D  
23 graphene foam [93], believed to support cell growth and proliferation, enhancing NSC differentiation  
24 into astrocytes and neurons. GC-MS metabolomics clearly distinguished the metabolome of NSCs  
25 grown in 3D graphene, from those grown in 2D graphene films or polystyrene surfaces, mainly in  
26 relation to increased amino acid incorporation and enhanced glucose metabolism and the authors sug-  
27 gest a possible association of the observed effects with pathways relevant in Parkinson's disease.

## 28 29 **6. Metabolomics of other SCs**

### 30 **6.1. Differentiation**

31 A study of perivascular SCs investigated differentiation within hydrogels of different stiffness,  
32 specifically following the processed through LC-MS metabolomics of cell extracts [94]. Interestingly,  
33 soft gels induced neuronal differentiation, whereas stiff and more rigid gels induced preferential chon-  
34 drogenic and osteogenic lineage, respectively. Metabolomics identified lysophosphatidic acid and  
35 cholesterol sulphate as particularly depleted in the latter two processed, respectively, and their specific  
36 needs were confirmed by posterior enrichment of culture media with such lipid moieties. This shows  
37 that integration of supramolecular biomaterials and tailored culture media may be effective in conduct-  
38 ing SC differentiation. A similar strategy was followed to improve differentiation of human adipose

1 tissue pericytes (or perivascular SCs) into chondrocytes [95], by using a peptide hydrogel and showing  
2 that LC-MS metabolomics detects different metabolic features between such method and conventional  
3 chemical induced chondrogenesis methods. The authors highlight the importance of metabolomics to  
4 investigate cell crosstalk with the microenvironment and discriminate between different differentiated  
5 cell phenotypes.

6 The idea that metabolite levels in culture media may direct and influence SC fate was pursued  
7 in a study comparing mouse haematopoietic SCs (HSCs) to restricted haematopoietic progenitors us-  
8 ing LC-MS metabolomics [96]. It was noted that each haematopoietic cell type had a distinct metabol-  
9 ic signature and that both human and mouse HSCs had unusually high levels of ascorbate, which de-  
10 creased with differentiation. It was suggested that this metabolite may regulate HSC function and help  
11 to suppress leukaemogenesis. Untargeted comprehensive LC-MS metabolomics of primary human  
12 skeletal muscle cells during myogenic progression showed significant changes in metabolomic pro-  
13 files in myoblasts undergoing proliferation and differentiation [97]. Pathway analyses revealed an  
14 interplay of different metabolic pathways in early and late differentiating cultures, shedding light into  
15 the maturation of muscle from progenitor myoblasts, potentially applicable in muscle regeneration and  
16 pathophysiology. In addition, lipid metabolism features, as evaluated by MS metabolomics [98] of  
17 human epidermal SCs revealed lipid accumulation during differentiation into keratinocytes, identify-  
18 ing ceramides and glucosylceramides as main players in the process.

## 20 **6.2. Other studies**

21 An initial NMR study of human hepatoblasts (hHBs) and human hepatic stem cells (hHpSCs)  
22 footprinting characterized cultures in in hyaluronan gels mixed with specific extra cellular components  
23 [99]. Another exometabolome NMR metabolomics study [100] (interestingly employing the projec-  
24 tions of 2D  $^1\text{H}$  J-resolved spectra, instead of the more typical approach of standard  $^1\text{H}$  spectra) was  
25 recently carried out to investigate the effect of simulated microgravity, which promotes a 3D environ-  
26 ment on the footprinting of human biliary tree stem/progenitor cells (hBTSCs), as well as of human  
27 hepatic cells (HepG2). Both cell types were cultured in a weightless environment obtained through a  
28 Rotatory Cell Culture system, compared to conditions under normal gravity. The produced 3D envi-  
29 ronments induced increased stemness and hindered differentiation of hBTSCs into mature hepatocytes.  
30 There were clear exometabolome changes, with microgravity inducing higher usage of glucose and  
31 lower glutamate and releasing higher levels of fermentation and ketogenesis product, compared to  
32 HepG2 cells. The exploitation of this behaviour of hBTSCs stemness maintenance contrasting with  
33 differentiation in hBTSCs-derived liver devices was discussed. A similar system was recently also  
34 used to test the effects of microgravity on epidermal SCs (EpSCs) [101], as viewed by LC-MS cell  
35 fingerprinting, and demonstrating significant impact on several metabolic pathways (including amino  
36 acid, lipids metabolisms).

37 In relation to MS-based studies, a CE-MS metabolomic analysis of [102] HSCs showed that a dif-  
38 ferent intracellular metabolic profile is exhibited under hypoxic conditions, namely by generating ATP  
39 by anaerobic glycolysis involving pyruvate dehydrogenase kinase. This report suggested that such

1 mechanism may be determinant in HSC quiescence and function. A subsequent untargeted LC-MS  
2 study of the endometabolome of spermatogonial stem cells (SSCs) upon deprivation of Glial cell line-  
3 derived neurotrophic factor (GdnF), known to be determinant for SSCs proliferation, was reported  
4 [103]. Decreases were noted in 11 intracellular metabolites, whereas other 3 were observed to in-  
5 crease. Within the former, glycylglycine was observed to positively affect SC proliferation, although  
6 no association with the expression levels of self-renewal genes was found.

## 8 **Future perspectives**

9 The state of the art of metabolomics in the study of SC properties and function is presented in this  
10 text, after a brief introduction to traditional and emerging analytical strategies used in cell metabolom-  
11 ics. Metabolomic strategies employ either MS- or NMR-based data, the former having been the chosen  
12 analytical tool in most reports. However, the complementarity of both techniques is made clear in this  
13 paper, while uncovering underexplored research analytical niches, for instance employing direct cell  
14 analysis (through HRMAS NMR of cell pellets or single-cell microscopy-based metabolomics). As a  
15 valuable hypotheses-generation platform, metabolomics requires suitable statistical data handling (in-  
16 cluding statistical validation strategies), as well as strategies to test biological hypotheses, for instance  
17 through bioinformatics metabolic pathway analysis, isotope tracing studies to validate putative  
18 up/down-regulation of specific pathways, or correlation with other omics data. In some reports, such  
19 interdisciplinary strategies have been reported, clearly indicating the need to strengthen such method-  
20 ologies, to ensure data robustness and demonstrate putative new biological hypotheses. Furthermore,  
21 the standardization standard operating procedures in relation to SC culture, harvesting, storage and  
22 handling for metabolomics would be of great value, particularly regarding cell numbers, cell status and  
23 passage, harvesting method, storage time/temperature and extraction methods.

24 Various aspects of MSCs behavior are identified as the most studied by metabolomics so far, fol-  
25 lowed by PSCs and NSCs, and only a few reports on other SC types. This text unveils, therefore, sev-  
26 eral additional SC types and research aspects as niches for future metabolomic applications, namely  
27 hematopoietic SCs, which hold a strong impact in clinical strategies. Some of the central ideas investi-  
28 gated so far comprise the metabolic impacts of origin tissue and donor, differentiation conditions, and  
29 other culture conditions (such as hypoxia) or media enrichment. In the case of PSCs, metabolic re-  
30 modeling, and their use to build disease models has also been addressed. Generally, studies have ad-  
31 dressed either or both endometabolome and exometabolome (including cell secretome), having meas-  
32 ured lipid species to a large extent, along with different types of polar metabolites involved in a variety  
33 of metabolic pathways. Recent advances draw attention to the importance of 3D culture environments,  
34 mechanical cues and/or media enrichment to guide differentiation into optimized particular lineages.

35 This review demonstrates the enticing potential of metabolomics strategies to significantly con-  
36 tribute to a deeper knowledge of SC behavior and identify cell performance biomarkers, which may, in  
37 time, become of particular importance for instance for identifying adequate donors/tissues for particu-  
38 lar ends or guiding differentiation into pure specific lineages. The evaluation of *in vivo* post-  
39 implantation SC performance is also particularly suited to metabolomic strategies (*e.g.* through bioflu-

ids), an approach which is presently still underexplored. Hence, either *in vitro* or *in vivo*, metabolomics has the undeniable potential of becoming of practical use in personalized clinical applications related to SC-based tissue regeneration strategies or disease characterization and follow-up.

## Acknowledgments

The authors are grateful to Dr. Iola F. Duarte for help in organizing some of the relevant literature.

## Declarations

**Funding** The authors acknowledge the Portuguese Foundation for Science and Technology (FCT) for co-funding the BIOIMPLANT project (PTDC/BTM-ORG/28835/2017) through the COMPETE2020 program and European Union fund FEDER (POCI-01-0145-FEDER-028835). CSHJ and KR are grateful to the same project for funding their contracts with the University of Aveiro. DSB acknowledges the Sociedade Portuguesa de Química and FCT for her PhD grant SFRH/BD/150655/2020. AMG acknowledges the CICECO-Aveiro Institute of Materials project, with references UIDB/50011/2020 & UIDP/50011/2020, financed by national funds through the FCT/MEC and when appropriate co-financed by FEDER under the PT2020 Partnership Agreement. The NMR spectrometer used in this work is part of the National NMR Network (PTNMR) and, partially supported by Infrastructure Project N° 022161 (co-financed by FEDER through COMPETE 2020, POCI and PORL and FCT through PIDDAC).

**Conflicts of interest** The authors have no conflicts of interest to declare that are relevant to the content of this article.

**Ethics approval** Not applicable

**Consent to participate** Not applicable

**Consent for publication** Not applicable

**Availability of data and material** Not applicable

**Code availability** Not applicable

**Authors' Contributions**

1 AMG had the idea for this review article; DSB, CSHJ, IMCM, and KMR performed the literature  
2 search and data analysis; AMG and DSB drafted the manuscript; JFM and MBO critically revised the  
3 manuscript; all authors read, revised and approved the final version of this work.

4

5

## 6 **Figure captions**

7

8 **Fig. 1. Scheme of a typical metabolomics workflow applicable to cell analysis.** LC-MS, liquid  
9 chromatography in tandem with mass spectrometry; GC-MS, gas chromatography in tandem with  
10 mass spectrometry; NMR, nuclear magnetic resonance spectroscopy; HRMAS NMR, high-resolution-  
11 magic-angle-spinning NMR. Some elements of this picture were adapted from Servier Medical Art  
12 (<https://smart.servier.com/>) licensed under a Creative Commons Attribution 3.0 Unported (CC BY  
13 3.0) license.

14

15 **Fig. 2. Stem cell metabolomics studies to date (excluding cancer stem cell research).** (A) Number  
16 of research papers published up to 15 January 2021 (\*), as a function of year and analytical technique  
17 employed: nuclear magnetic resonance spectroscopy (NMR), mass spectrometry (MS), and/or others  
18 (including Fourier-transform infrared spectroscopy and Raman spectroscopy). (B) Number of research  
19 papers on different types of stem cells (colour code), distributed by main research topics. Web of Sci-  
20 ence searches using [stem cell\*] AND [metabolomic\* OR metabonomic\* OR (metabol\* AND (profil\*  
21 OR fingerprint))] and [stem cell\*] AND [lipidomic\*]. These comprise studies of different differentia-  
22 tion conditions in 2D and 3D cultures, and/or nanotopographic surfaces; exposure of stem cell (SCs) to  
23 several other conditions (*e.g.* different O<sub>2</sub> availability, presence/absence of clinically relevant com-  
24 pounds); metabolome analysis of one or more SC types, donors and/or tissue sources; studies of SC  
25 aging, senescence and autophagy; and several disease models. MSCs: Mesenchymal Stem Cells; PSC:  
26 Pluripotent Stem Cells; NSC: Neural Stem Cells.

27

28 **Fig. 3. Typical <sup>1</sup>H NMR spectrum of subcutaneous mouse adipose-derived mesenchymal stem**  
29 **cells (mAMSCs) culture medium 72 h after reaching 75% confluency (600 MHz, 30.0°C).** Dul-  
30 becco's modified Eagle's medium-high glucose (DMEM-HG) was supplemented with 2 mM L-  
31 glutamine-L-alanyl (stable glutamine), 1 mM pyruvate, 100 U/ml penicillin, 100µg/ml streptomycin,  
32 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and 10% fetal calf serum. Ma-  
33 jor metabolite peak assignments are indicated. Adapted from reference [17], licensed under Creative  
34 Commons Attribution 4.0 International (CC BY 4.0) license.

35

36 **Fig. 4. Multivariate statistical analyses of the differences between the exometabolomes (72 h af-**  
37 **ter 75% confluency) of subcutaneous mAMSCs (S-ASC) and visceral mAMSCs (V-ASC).** Cul-  
38 ture medium composition as described in Fig. 3. NMR absolute spectra bins after subtraction of the

1 culture medium signal analysis performed on NMR spectra buckets without normalization to the cell  
2 number. (A) Untargeted principal component analysis (PCA) readily evidences the tissue of origin as a  
3 major source of the dataset variance. Score plot (PC1 and PC2;  $n = 11$ ,  $R^2 = 0.962$ , and  $Q^2 = 0.843$  on 5  
4 PC). (B and C) Orthogonal partial least squares discriminant analysis (OPLS-DA, supervised multivar-  
5 iate analysis) shows a strong discrimination between subcutaneous mAMSCs (S-ASC) and visceral  
6 mAMSCs (V-ASC), characterized by high values of goodness-of-fit model parameters ( $R^2X=0.796$ ,  
7  $R^2Y=0.991$ , and  $Q^2=0.969$ ). The discrimination robustness was validated by resampling 1000 times  
8 the model under the null hypothesis (data not shown), and the analysis of variance (CV-ANOVA) of  
9 the model led to a p-value of  $1.20 \times 10^{-4}$ . (B) Score plot discriminating S-ASC (in green) and V-ASC  
10 (in blue). (C) Loading plot complemented by color-coded correlation indicating statistically signifi-  
11 cant signals. (1) leucine, (2) valine, (3) lactate, (4) alanine, (5) acetate, (6) glutamine, (7) citrate, (8)  
12 glucose, (9) tyrosine, (10) phenylalanine. (D) Simplified non-quantitative representation of the main  
13 metabolic pathways (represented in italics) in actively dividing mAMSCs. Colors identify the meta-  
14 bolic pathways analysed in this study. EAA, essential amino acids; mAMSCs, mouse adipose-derived  
15 mesenchymal stem cells; TCA, tricarboxylic acid cycle. Adapted from reference [17], licensed under  
16 Creative Commons Attribution 4.0 International (CC BY 4.0) license.

17

18 **Fig. 5. OPLS-DA scores plot of LC-MS data from mBMMSCs conditioned medium samples**  
19 **(controls and dexamethasone-induced osteogenesis), and their corresponding medium-only**  
20 **blanks, analysed after 5, 10 and 15 days in culture.** (A) Combined controls and OS conditioned  
21 samples vs. their respective medium-only blanks ( $R^2=0.841$  and  $Q^2 = 0.644$ ). (B and C) Metabolic  
22 trajectory over time (arrows) of control samples (B,  $R^2 = 0.991$  and  $Q^2 = 0.756$ ) and OS (C,  $R^2 = 0.992$   
23 and  $Q^2 = 0.777$ ). LC-MS, Liquid chromatography mass spectrometry; mBMMSCs, Mouse bone-  
24 marrow mesenchymal stem cells; OPLS-DA, Orthogonal partial least squares discriminant analysis;  
25 OS, osteogenesis. Adapted from reference [32].

26

27 **Fig. 6. Untargeted LC-MS metabolomics analysis of hBMMSCs after 1 and 2 weeks of**  
28 **nanostimulation at 30 nm (N30) and 90 nm (N90) amplitudes.** (A) Lipid heatmaps of N30 and N90  
29 compared to control conditions. (B) Principal component analysis (PCA) of lipid data, compared to  
30 controls. (C) Observed metabolite changes in ROS pathways following 1 week of culture under N30  
31 or N90 conditions. (D) Potential pathways derived from the heatmap data. The data indicate the acti-  
32 vation of ROS and redox-balancing pathway occurs in conditions of increasing nanostimulation ampli-  
33 tude. LC-MS, Liquid chromatography mass spectrometry; mBMMSCs, Mouse bone-marrow  
34 mesenchymal stem cells; ROS, reactive oxygen species. Adapted from reference [45], licensed under  
35 Creative Commons Attribution 4.0 International (CC BY 4.0) license.

36

37 **Fig. 7.  $^1\text{H}$  NMR spectra of media samples before (control samples) and after exposure to human**  
38 **umbilical cord mesenchymal stem cells (hUCMSCs) and plasma from umbilical cord blood.** (A)  
39 Dulbecco's Modified Eagle Medium/Nutrient Mixture (DMEM, Gibco) before SC exposure. (B)

1 DMEM after 24 h hUCMSCs exposure (exometabolome). (C) Commercial medium (from PromoCell,  
2 LabClinics, Promocell, C-28010) after 48 h SC exposure (exometabolome). (D and E) Commercial  
3 medium after 24 h hUCMSCs exposure (exometabolome). (F) Commercial medium before hUCMSCs  
4 exposure. (G-K) Plasma samples from different donors. Peak assignment: 1, Lipids; 2, Isoleu-  
5 cine/Leucine/Valine; 3, Ethanol; 4, b-hydroxybutyrate; 5, Lipids; 6, Threonine; 7, Lactate; 8, Alanine;  
6 9, Lysine/Arginine; 10, Acetate; 11, Glutamate; 12, Glutamine; 13, Methionine; 14, Pyruvate; 15,  
7 Citric acid; 16, Choline; 17, Inositol; 18, a-Glucose; 19, b-Glucose; 20, Tyrosine; 21, Phenylalanine;  
8 22, Histidine; 23, Nicotinamide; 24, Tryptophan; 25, Thiamine; 26, Formate; 27, Urea; 28, Purines.  
9 Adapted from reference [56], licensed under Creative Commons Attribution 4.0 International (CC BY  
10 4.0) license.  
11



## 1 Tables

2

**Table 1. Selected review papers that emphasize the importance and potential of stem cells (SCs) metabolomics.**

Reference	SC type(s)	Analytical technique	Main subject
[13]	PSCs and adult SCs	MS	SC lipidome and its association with genetic and/or pharmacological features for SC regulation
[11]	MSCs	NMR/MS	Elucidation of MSC function (intracellular metabolites and secretome)
[1]	SCs in general	NMR/MS	Targeted and untargeted metabolomics to study stem and progenitor cells
[12]	Adipose SCs	MS	Lipidomics of adipocyte differentiation, physiology and pathophysiology

**MS, mass spectrometry; MSC, mesenchymal SCs; NMR, nuclear magnetic resonance spectroscopy; PSC, Pluripotent SCs.**

3

## 1   **References**

- 2   1.     Martano, G., Borroni, E. M., Lopci, E., Cattaneo, M. G., Mattioli, M., Bachi, A., Decimo, I., &  
3       Bifari, F. (2019). Metabolism of stem and progenitor cells: Proper methods to answer specific  
4       questions. *Frontiers in Molecular Neuroscience*, *12*, 151 (17 pages).  
5       <https://doi.org/10.3389/fnmol.2019.00151>
- 6   2.     Palacios-Ferrer, J. L., García-Ortega, M. B., Gallardo-Gómez, M., García, M. Á., Díaz, C.,  
7       Boulaiz, H., Valdivia, J., Jurado, J. M., Almazan-Fernandez, F. M., Arias-Santiago, S.,  
8       Amezcuca, V., Peinado, H., Vicente, F., Pérez del Palacio, J., & Marchal, J. A. (2021).  
9       Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant  
10      melanoma. *Molecular Oncology*, *15*(2), 407–428. <https://doi.org/10.1002/1878-0261.12823>
- 11 3.     Segers, K., Declerck, S., Mangelings, D., Heyden, Y. Vander, & Eeckhaut, A. Van. (2019).  
12      Analytical techniques for metabolomic studies: A review. *Bioanalysis*, *11*(24), 2297–2318.  
13      <https://doi.org/10.4155/bio-2019-0014>
- 14 4.     Srivastava, A., Evans, K. J., Sexton, A. E., Schofield, L., & Creek, D. J. (2017). Metabolomics-  
15      Based Elucidation of Active Metabolic Pathways in Erythrocytes and HSC-Derived  
16      Reticulocytes. *Journal of Proteome Research*, *16*(4), 1492–1505.  
17      <https://doi.org/10.1021/acs.jproteome.6b00902>
- 18 5.     Zhang, H., Badur, M. G., Divakaruni, A. S., Parker, S. J., Jäger, C., Hiller, K., Murphy, A. N.,  
19      & Metallo, C. M. (2016). Distinct Metabolic States Can Support Self-Renewal and Lipogenesis  
20      in Human Pluripotent Stem Cells under Different Culture Conditions. *Cell Reports*, *16*(6),  
21      1536–1547. <https://doi.org/10.1016/j.celrep.2016.06.102>
- 22 6.     Del Favero, G., Bonifacio, A., Rowland, T. J., Gao, S., Song, K., Sergo, V., Adler, E. D.,  
23      Mestroni, L., Sbaizero, O., & Taylor, M. R. G. (2020). Danon Disease-Associated LAMP-2  
24      Deficiency Drives Metabolic Signature Indicative of Mitochondrial Aging and Fibrosis in  
25      Cardiac Tissue and hiPSC-Derived Cardiomyocytes. *Journal of Clinical Medicine*, *9*(8), 2457  
26      (20 pages). <https://doi.org/10.3390/jcm9082457>
- 27 7.     Kostidis, S., Addie, R. D., Morreau, H., Mayboroda, O. A., & Giera, M. (2017). Quantitative  
28      NMR analysis of intra- and extracellular metabolism of mammalian cells: A tutorial. *Analytica*  
29      *Chimica Acta*, *980*, 1–24. <https://doi.org/10.1016/j.aca.2017.05.011>
- 30 8.     Duarte, I., Lamego, I., Marques, J., Marques, M., Blaise, B., & Gil, A. M. (2010). A Nuclear  
31      Magnetic Resonance (NMR) study of the effect of Cisplatin on the metabolic profile of MG-63  
32      osteosarcoma cells. *Journal of Proteome Research*, *9*(11), 5877–5886.  
33      <https://doi.org/10.1021/pr100635n>
- 34 9.     De Luca, M., Aiuti, A., Cossu, G., Parmar, M., Pellegrini, G., & Robey, P. G. (2019).  
35      Advances in stem cell research and therapeutic development. *Nature Cell Biology*, *21*(7), 801–  
36      811. <https://doi.org/10.1038/s41556-019-0344-z>
- 37 10.    Andrzejewska, A., Lukomska, B., & Janowski, M. (2019). Concise Review: Mesenchymal  
38      Stem Cells: From Roots to Boost. *STEM CELLS*, *37*(7), 855–864.

- 1 <https://doi.org/10.1002/stem.3016>
- 2 11. Goodarzi, P., Alavi-Moghadam, S., Payab, M., Larijani, B., Rahim, F., Gilany, K., Bana, N.,  
3 Tayanloo-Beik, A., Heravani, N. F., Hadavandkhani, M., & Arjmand, B. (2019). Metabolomics  
4 analysis of mesenchymal stem cells. *International Journal of Molecular and Cellular*  
5 *Medicine*, 8(1), 30–40. <https://doi.org/10.22088/IJMCM.BUMS.8.2.30>
- 6 12. Lapid, K., & Graff, J. M. (2017). Form(ul)ation of adipocytes by lipids. *Adipocyte*, 6(3), 176–  
7 186. <https://doi.org/10.1080/21623945.2017.1299298>
- 8 13. Clémot, M., Sênos Demarco, R., & Jones, D. L. (2020). Lipid Mediated Regulation of Adult  
9 Stem Cell Behavior. *Frontiers in Cell and Developmental Biology*, 8, 115 (17 pages).  
10 <https://doi.org/10.3389/fcell.2020.00115>
- 11 14. Liaw, L., Prudovsky, I., Koza, R. A., Anunciado-Koza, R. V., Siviski, M. E., Lindner, V.,  
12 Friesel, R. E., Rosen, C. J., Baker, P. R. S., Simons, B., & Vary, C. P. H. (2016). Lipid  
13 Profiling of In Vitro Cell Models of Adipogenic Differentiation: Relationships With Mouse  
14 Adipose Tissues. *Journal of Cellular Biochemistry*, 117, 2182–2193.  
15 <https://doi.org/10.1002/jcb.25522>
- 16 15. Lee, S. J., Yi, T. G., Ahn, S. H., Lim, D. K., Kim, S. na, Lee, H. J., Cho, Y. K., Lim, J. Y.,  
17 Sung, J. H., Yun, J. H., Lim, J., Song, S. U., & Kwon, S. W. (2018). Comparative study on  
18 metabolite level in tissue-specific human mesenchymal stem cells by an ultra-performance  
19 liquid chromatography quadrupole time of flight mass spectrometry. *Analytica Chimica Acta*,  
20 1024, 112–122. <https://doi.org/10.1016/j.aca.2018.04.018>
- 21 16. Li, J. Z., Qu, H., Wu, J., Zhang, F., Jia, Z. B., Sun, J. Y., Lv, B., Kang, Y., Jiang, S. L., &  
22 Kang, K. (2018). Metabolic profiles of adipose-derived and bone marrow-derived stromal cells  
23 from elderly coronary heart disease patients by capillary liquid chromatography quadrupole  
24 time-of-flight mass spectrometry. *International Journal of Molecular Medicine*, 41(1), 184–  
25 194. <https://doi.org/10.3892/ijmm.2017.3198>
- 26 17. Lefevre, C., Panthu, B., Naville, D., Guibert, S., Pinteur, C., Elena-Herrmann, B., Vidal, H.,  
27 Rautureau, G. J. P., & Mey, A. (2019). Metabolic phenotyping of adipose-derived stem cells  
28 reveals a unique signature and intrinsic differences between fat pads. *Stem Cells International*,  
29 2019, Article ID 9323864 (16 pages). <https://doi.org/10.1155/2019/9323864>
- 30 18. Caseiro, A. R., Pedrosa, S. S., Ivanova, G., Branquinho, M. V., Almeida, A., Faria, F.,  
31 Amorim, I., Pereira, T., & Maurício, A. C. (2019). Mesenchymal Stem/ Stromal Cells  
32 metabolomic and bioactive factors profiles: A comparative analysis on the Umbilical Cord and  
33 Dental Pulp derived Stem/ Stromal Cells secretome. *PLoS ONE*, 14(11), e0221378 (33 pages).  
34 <https://doi.org/10.1371/journal.pone.0221378>
- 35 19. Mastrangelo, A., Panadero, M. I., Perez, L. M., Galvez, B. G., Garcia, A., Barbas, C., &  
36 Ruperez, F. J. (2016). New insight on obesity and adipose-derived stem cells using  
37 comprehensive metabolomics. *Biochemical Journal*, 473(14), 2187–2203.  
38 <https://doi.org/10.1042/BCJ20160241>
- 39 20. Devito, L., Klontzas, M. E., Cvoro, A., Galleu, A., Simon, M., Hobbs, C., Dazzi, F.,

- 1 Mantalaris, A., Khalaf, Y., & Ilic, D. (2019). Comparison of human isogenic Wharton's jelly  
2 MSCs and iPSC-derived MSCs reveals differentiation-dependent metabolic responses to IFNG  
3 stimulation. *Cell Death and Disease*, *10*(4), 277 (13 pages). [https://doi.org/10.1038/s41419-](https://doi.org/10.1038/s41419-019-1498-0)  
4 019-1498-0
- 5 21. Shi, C., Wang, X., Wu, S., Zhu, Y., Chung, L. W. K., & Mao, H. (2008). HRMAS 1 H-NMR  
6 measured changes of the metabolite profile as mesenchymal stem cells differentiate to targeted  
7 fat cells in vitro : implications for non-invasive monitoring of stem cell differentiation in vivo.  
8 *Journal of Tissue Engineering and Regenerative Medicine*, *2*(8), 482–490.  
9 <https://doi.org/10.1002/term.120>
- 10 22. Xu, Z.-F. (2012). Human umbilical mesenchymal stem cell and its adipogenic differentiation:  
11 Profiling by nuclear magnetic resonance spectroscopy. *World Journal of Stem Cells*, *4*(4), 21–  
12 27. <https://doi.org/10.4252/wjsc.v4.i4.21>
- 13 23. Bojin, F. M., Gruia, A. T., Cristea, M. I., Ordodi, V. L., Paunescu, V., & Mic, F. A. (2012).  
14 Adipocytes differentiated in vitro from rat mesenchymal stem cells lack essential free fatty  
15 acids compared to adult adipocytes. *Stem Cells and Development*, *21*(4), 507–512.  
16 <https://doi.org/10.1089/scd.2011.0491>
- 17 24. Gruia, A. T., Suci, M., Barbu-Tudoran, L., Azghadi, S. M. R., Cristea, M. I., Nica, D. V,  
18 Vaduva, A., Muntean, D., Mic, A. A., & Mic, F. A. (2016). Mesenchymal Stromal Cells  
19 Differentiating to Adipocytes Accumulate Autophagic Vesicles Instead of Functional Lipid  
20 Droplets. *Journal of Cellular Physiology*, *231*(4), 863–875. <https://doi.org/10.1002/jcp.25177>
- 21 25. Klemenz, Meyer, Ekat, Bartels, Traxler, Schubert, Kamp, Miekisch, & Peters. (2019).  
22 Differences in the Emission of Volatile Organic Compounds (VOCs) between Non-  
23 Differentiating and Adipogenically Differentiating Mesenchymal Stromal/Stem Cells from  
24 Human Adipose Tissue. *Cells*, *8*(7), 697 (14 pages). <https://doi.org/10.3390/cells8070697>
- 25 26. Ouellette, M. È., Bérubé, J. C., Bourget, J. M., Vallée, M., Bossé, Y., & Fradette, J. (2019).  
26 Linoleic acid supplementation of cell culture media influences the phospholipid and lipid  
27 profiles of human reconstructed adipose tissue. *PLoS ONE*, *14*(10), e0224228 (22 pages).  
28 <https://doi.org/10.1371/journal.pone.0224228>
- 29 27. Rampler, E., Egger, D., Schoeny, H., Rusz, M., Pacheco, M. P., Marino, G., Kasper, C.,  
30 Naegele, T., & Koellensperger, G. (2019). The Power of LC-MS Based Multiomics: Exploring  
31 Adipogenic Differentiation of Human Mesenchymal Stem/Stromal Cells. *Molecules*, *24*(19),  
32 3615 (19 pages). <https://doi.org/10.3390/molecules24193615>
- 33 28. Silva, C. G. da, Barretto, L. S. de S., Lo Turco, E. G., Santos, A. de L., Lessio, C., Martins  
34 Júnior, H. A., & Almeida, F. G. de. (2020). Lipidomics of mesenchymal stem cell  
35 differentiation. *Chemistry and Physics of Lipids*, *232*, 104964 (9 pages).  
36 <https://doi.org/10.1016/j.chemphyslip.2020.104964>
- 37 29. Mitchell, A., Ashton, L., Yang, X. B., Goodacre, R., Smith, A., & Kirkham, J. (2015).  
38 Detection of early stage changes associated with adipogenesis using Raman spectroscopy under  
39 aseptic conditions. *Cytometry Part A*, *87*(11), 1012–1019. <https://doi.org/10.1002/cyto.a.22777>

- 1 30. Liu, Z., Tang, Y., Chen, F., Liu, X., Liu, Z., Zhong, J., Hu, J., & Lü, J. (2016). Synchrotron  
2 FTIR microspectroscopy reveals early adipogenic differentiation of human mesenchymal stem  
3 cells at single-cell level. *Biochemical and Biophysical Research Communications*, 478(3),  
4 1286–1291. <https://doi.org/10.1016/j.bbrc.2016.08.112>
- 5 31. Lorthongpanich, C., Thumanu, K., Tangkiettrakul, K., Jiamvoraphong, N., Laowtammathron,  
6 C., Damkham, N., U-Pratya, Y., & Issaragrisil, S. (2019). YAP as a key regulator of adipo-  
7 osteogenic differentiation in human MSCs. *Stem Cell Research and Therapy*, 10(1), 402 (12  
8 pages). <https://doi.org/10.1186/s13287-019-1494-4>
- 9 32. Surrati, A., Linforth, R., Fisk, I. D., Sottile, V., & Kim, D. H. (2016). Non-destructive  
10 characterisation of mesenchymal stem cell differentiation using LC-MS-based metabolite  
11 footprinting. *Analyst*, 141(12), 3776–3787. <https://doi.org/10.1039/c6an00170j>
- 12 33. Klontzas, M. E., Vernardis, S. I., Heliotis, M., Tsiridis, E., & Mantalaris, A. (2017).  
13 Metabolomics Analysis of the Osteogenic Differentiation of Umbilical Cord Blood  
14 Mesenchymal Stem Cells Reveals Differential Sensitivity to Osteogenic Agents. *Stem Cells  
15 and Development*, 26(10), 723–733. <https://doi.org/10.1089/scd.2016.0315>
- 16 34. Levental, K. R., Surma, M. A., Skinkle, A. D., Lorent, J. H., Zhou, Y., Klose, C., Chang, J. T.,  
17 Hancock, J. F., & Levental, I. (2017). W-3 Polyunsaturated Fatty Acids Direct Differentiation  
18 of the Membrane Phenotype in Mesenchymal Stem Cells To Potentiate Osteogenesis. *Science  
19 Advances*, 3(11), eaao1193 (15 pages). <https://doi.org/10.1126/sciadv.aao1193>
- 20 35. Gaur, D., Yogalakshmi, Y., Kulanthaivel, S., Agarwal, T., Mukherjee, D., Prince, A., Tiwari,  
21 A., Maiti, T. K., Pal, K., Giri, S., Saleem, M., & Banerjee, I. (2018). Osteoblast-Derived Giant  
22 Plasma Membrane Vesicles Induce Osteogenic Differentiation of Human Mesenchymal Stem  
23 Cells. *Advanced Biosystems*, 2(9), 1800093 (12 pages). <https://doi.org/10.1002/adbi.201800093>
- 24 36. Zhao, G., Zhong, H., Rao, T., & Pan, Z. (2020). Metabolomic Analysis Reveals That the  
25 Mechanism of Astaxanthin Improves the Osteogenic Differentiation Potential in Bone Marrow  
26 Mesenchymal Stem Cells. *Oxidative Medicine and Cellular Longevity*, 2020, Article ID  
27 3427430 (11 pages). <https://doi.org/10.1155/2020/3427430>
- 28 37. Tsimbouri, P. M., McMurray, R. J., Burgess, K. V., Alakpa, E. V., Reynolds, P. M., Murawski,  
29 K., Kingham, E., Oreffo, R. O. C., Gadegaard, N., & Dalby, M. J. (2012). Using  
30 nanotopography and metabolomics to identify biochemical effectors of multipotency. *ACS  
31 Nano*, 6(11), 10239–10249. <https://doi.org/10.1021/nn304046m>
- 32 38. McNamara, L. E., Sjöström, T., Burgess, K. E. V., Kim, J. J. W., Liu, E., Gordonov, S.,  
33 Moghe, P. V., Meek, R. M. D., Oreffo, R. O. C., Su, B., & Dalby, M. J. (2011). Skeletal stem  
34 cell physiology on functionally distinct titania nanotopographies. *Biomaterials*, 32(30), 7403–  
35 7410. <https://doi.org/10.1016/j.biomaterials.2011.06.063>
- 36 39. Seras-Franzoso, J., Tsimbouri, P. M., Burgess, K. V., Unzueta, U., Garcia-Fruitos, E.,  
37 Vazquez, E., Villaverde, A., & Dalby, M. J. (2014). Topographically targeted osteogenesis of  
38 mesenchymal stem cells stimulated by inclusion bodies attached to polycaprolactone surfaces.  
39 *Nanomedicine*, 9(2), 207–220. <https://doi.org/10.2217/nnm.13.43>

- 1 40. Roberts, J. N., Sahoo, J. K., McNamara, L. E., Burgess, K. V., Yang, J., Alakpa, E. V.,  
2 Anderson, H. J., Hay, J., Turner, L. A., Yarwood, S. J., Zelzer, M., Oreffo, R. O. C., Ulijn, R.  
3 V., & Dalby, M. J. (2016). Dynamic Surfaces for the Study of Mesenchymal Stem Cell Growth  
4 through Adhesion Regulation. *ACS Nano*, *10*(7), 6667–6679.  
5 <https://doi.org/10.1021/acsnano.6b01765>
- 6 41. Amer, M. H., Alvarez-Paino, M., McLaren, J., Pappalardo, F., Trujillo, S., Wong, J. Q.,  
7 Shrestha, S., Abdelrazig, S., Stevens, L. A., Lee, J. B., Kim, D. H., González-García, C.,  
8 Needham, D., Salmerón-Sánchez, M., Shakesheff, K. M., Alexander, M. R., Alexander, C., &  
9 Rose, F. R. (2021). Designing topographically textured microparticles for induction and  
10 modulation of osteogenesis in mesenchymal stem cell engineering. *Biomaterials*, *266*(June  
11 2020), 120450 (17 pages). <https://doi.org/10.1016/j.biomaterials.2020.120450>
- 12 42. Klontzas, M. E., Reakasame, S., Silva, R., Morais, J. C. F., Vernardis, S., MacFarlane, R. J.,  
13 Heliotis, M., Tsiridis, E., Panoskaltis, N., Boccaccini, A. R., & Mantalaris, A. (2019).  
14 Oxidized alginate hydrogels with the GHK peptide enhance cord blood mesenchymal stem cell  
15 osteogenesis: A paradigm for metabolomics-based evaluation of biomaterial design. *Acta*  
16 *Biomaterialia*, *88*, 224–240. <https://doi.org/10.1016/j.actbio.2019.02.017>
- 17 43. Bow, A., Jackson, B., Griffin, C., Howard, S., Castro, H., Campagna, S., Biris, A. S.,  
18 Anderson, D. E., Bourdo, S., & Dhar, M. (2020). Multiomics Evaluation of Human Fat-  
19 Derived Mesenchymal Stem Cells on an Osteobiologic Nanocomposite. *BioResearch Open*  
20 *Access*, *9*(1), 37–50. <https://doi.org/10.1089/biores.2020.0005>
- 21 44. Tsimbouri, P. M., Childs, P. G., Pemberton, G. D., Yang, J., Jayawarna, V., Orapiriyakul, W.,  
22 Burgess, K., González-García, C., Blackburn, G., Thomas, D., Vallejo-Giraldo, C., Biggs, M.  
23 J. P., Curtis, A. S. G., Salmerón-Sánchez, M., Reid, S., & Dalby, M. J. (2017). Stimulation of  
24 3D osteogenesis by mesenchymal stem cells using a nanovibrational bioreactor. *Nature*  
25 *Biomedical Engineering*, *1*(9), 758–770. <https://doi.org/10.1038/s41551-017-0127-4>
- 26 45. Orapiriyakul, W., Tsimbouri, M. P., Childs, P., Campsie, P., Wells, J., Fernandez-Yague, M.  
27 A., Burgess, K., Tanner, K. E., Tassieri, M., Meek, D., Vassalli, M., Biggs, M. J. P., Salmeron-  
28 Sanchez, M., Oreffo, R. O. C., Reid, S., & Dalby, M. J. (2020). Nanovibrational Stimulation of  
29 Mesenchymal Stem Cells Induces Therapeutic Reactive Oxygen Species and Inflammation for  
30 Three-Dimensional Bone Tissue Engineering. *ACS Nano*, *14*(8), 10027–10044.  
31 <https://doi.org/10.1021/acsnano.0c03130>
- 32 46. Gärtner, A., Pereira, T., Armada-da-Silva, P. A. S., Amorim, I., Gomes, R., Ribeiro, J., França,  
33 M. L., Lopes, C., Porto, B., Sousa, R., Bombaci, A., Ronchi, G., Fregnan, F., Varejão, A. S. P.,  
34 Luís, A. L., Geuna, S., & Maurício, A. C. (2012). Use of poly(DL-lactide- $\epsilon$ -caprolactone)  
35 membranes and mesenchymal stem cells from the Wharton's jelly of the umbilical cord for  
36 promoting nerve regeneration in axonotmesis: In vitro and in vivo analysis. *Differentiation*,  
37 *84*(5), 355–365. <https://doi.org/10.1016/j.diff.2012.10.001>
- 38 47. Jang, M. Y., Chun, S. I., Mun, C. W., Hong, K. S., & Shin, J. W. (2013). Evaluation of  
39 Metabolomic Changes as a Biomarker of Chondrogenic Differentiation in 3D-cultured Human

- 1 Mesenchymal Stem Cells Using Proton (1H) Nuclear Magnetic Resonance Spectroscopy. *PLoS*  
2 *ONE*, 8(10), e78325 (12 pages). <https://doi.org/10.1371/journal.pone.0078325>
- 3 48. Rocha, B., Cillero-Pastor, B., Eijkel, G., Bruinen, A. L., Ruiz-Romero, C., Heeren, R. M. A., &  
4 Blanco, F. J. (2015). Characterization of lipidic markers of chondrogenic differentiation using  
5 mass spectrometry imaging. *Proteomics*, 15(4), 702–713.  
6 <https://doi.org/10.1002/pmic.201400260>
- 7 49. Kwon, S. Y., Chun, S. Y., Ha, Y. S., Kim, D. H., Kim, J., Song, P. H., Kim, H. T., Yoo, E. S.,  
8 Kim, B. S., & Kwon, T. G. (2017). Hypoxia Enhances Cell Properties of Human Mesenchymal  
9 Stem Cells. *Tissue Engineering and Regenerative Medicine*, 14(5), 595–604.  
10 <https://doi.org/10.1007/s13770-017-0068-8>
- 11 50. Muñoz, N., Kim, J., Liu, Y., Logan, T. M., & Ma, T. (2014). Gas chromatography-mass  
12 spectrometry analysis of human mesenchymal stem cell metabolism during proliferation and  
13 osteogenic differentiation under different oxygen tensions. *Journal of Biotechnology*, 169(1),  
14 95–102. <https://doi.org/10.1016/j.jbiotec.2013.11.010>
- 15 51. Georgi, N., Cillero-Pastor, B., Eijkel, G. B., Periyasamy, P. C., Kiss, A., Van Blitterswijk, C.,  
16 Post, J. N., Heeren, R. M. A., & Karperien, M. (2015). Differentiation of Mesenchymal Stem  
17 Cells under Hypoxia and Normoxia: Lipid Profiles Revealed by Time-of-Flight Secondary Ion  
18 Mass Spectrometry and Multivariate Analysis. *Analytical Chemistry*, 87(7), 3981–3988.  
19 <https://doi.org/10.1021/acs.analchem.5b00114>
- 20 52. Lakatos, K., Kalomoiris, S., Merkely, B., Nolta, J. A., & Fierro, F. A. (2016). Mesenchymal  
21 Stem Cells Respond to Hypoxia by Increasing Diacylglycerols. *Journal of Cellular*  
22 *Biochemistry*, 117(2), 300–307. <https://doi.org/10.1002/jcb.25292>
- 23 53. Wang, D., Chen, D., Yu, J., Liu, J., Shi, X., Sun, Y., Pan, Q., Luo, X., Yang, J., Li, Y., Cao, H.,  
24 Li, L., & Li, L. (2018). Impact of Oxygen Concentration on Metabolic Profile of Human  
25 Placenta-Derived Mesenchymal Stem Cells As Determined by Chemical Isotope Labeling LC-  
26 MS. *Journal of Proteome Research*, 17(5), 1866–1878.  
27 <https://doi.org/10.1021/acs.jproteome.7b00887>
- 28 54. Showalter, M. R., Wancewicz, B., Fiehn, O., Archard, J. A., Clayton, S., Wagner, J., Deng, P.,  
29 Halmai, J., Fink, K. D., Bauer, G., Fury, B., Perotti, N. H., Apperson, M., Butters, J., Belafsky,  
30 P., Farwell, G., Kuhn, M., Nolta JA, Anderson, J. D. (2019). Primed mesenchymal stem cells  
31 package exosomes with metabolites associated with immunomodulation. *Biochemical and*  
32 *Biophysical Research Communications*, 512(4), 729–735.  
33 <https://doi.org/10.1016/j.bbrc.2019.03.119>
- 34 55. Fujisawa, K., Takami, T., Okada, S., Hara, K., Matsumoto, T., Yamamoto, N., Yamasaki, T., &  
35 Sakaida, I. (2018). Analysis of Metabolomic Changes in Mesenchymal Stem Cells on  
36 Treatment with Desferrioxamine as a Hypoxia Mimetic Compared with Hypoxic Conditions.  
37 *Stem Cells*, 36(8), 1226–1236. <https://doi.org/10.1002/stem.2826>
- 38 56. Pereira, T., Ivanova, G., Caseiro, A. R., Barbosa, P., Bártolo, P. J., Santos, J. D., Luís, A. L., &  
39 Maurício, A. C. (2014). MSCs conditioned media and umbilical cord blood plasma

- 1 metabolomics and composition. *PLoS ONE*, 9(11), e113769.  
2 <https://doi.org/10.1371/journal.pone.0113769>
- 3 57. Liu, Y., Muñoz, N., Bunnell, B. A., Logan, T. M., & Ma, T. (2015). Density-Dependent  
4 Metabolic Heterogeneity in Human Mesenchymal Stem Cells. *STEM CELLS*, 33(11), 3368–  
5 3381. <https://doi.org/10.1002/stem.2097>
- 6 58. Huang, D., Gao, Y., Wang, S., Zhang, W., Cao, H., Zheng, L., Chen, Y., Zhang, S., & Chen, J.  
7 (2020). Impact of low-intensity pulsed ultrasound on transcription and metabolite compositions  
8 in proliferation and functionalization of human adipose-derived mesenchymal stromal cells.  
9 *Scientific Reports*, 10(1), 13690 (19 pages). <https://doi.org/10.1038/s41598-020-69430-z>
- 10 59. Kim, J. S., Kim, E. J., Kim, H. J., Yang, J. Y., Hwang, G. S., & Kim, C. W. (2011). Proteomic  
11 and metabolomic analysis of H<sub>2</sub>O<sub>2</sub>-induced premature senescent human mesenchymal stem  
12 cells. *Experimental Gerontology*, 46(6), 500–510. <https://doi.org/10.1016/j.exger.2011.02.012>
- 13 60. Lu, X., Chen, Y., Wang, H., Bai, Y., Zhao, J., Zhang, X., Liang, L., Chen, Y., Ye, C., Li, Y.,  
14 Zhang, Y., Li, Y., & Ma, T. (2019). Integrated Lipidomics and Transcriptomics  
15 Characterization upon Aging-Related Changes of Lipid Species and Pathways in Human Bone  
16 Marrow Mesenchymal Stem Cells. *Journal of Proteome Research*, 18(5), 2065–2077.  
17 <https://doi.org/10.1021/acs.jproteome.8b00936>
- 18 61. Fernandez-Rebollo, E., Franzen, J., Goetzke, R., Hollmann, J., Ostrowska, A., Oliverio, M.,  
19 Sieben, T., Rath, B., Kornfeld, J. W., & Wagner, W. (2020). Senescence-Associated  
20 Metabolomic Phenotype in Primary and iPSC-Derived Mesenchymal Stromal Cells. *Stem Cell*  
21 *Reports*, 14(2), 201–209. <https://doi.org/10.1016/j.stemcr.2019.12.012>
- 22 62. Sun, Y., Chen, D., Liu, J., Xu, Y., Shi, X., Luo, X., Pan, Q., Yu, J., Yang, J., Cao, H., Li, L., &  
23 Li, L. (2018). Metabolic profiling associated with autophagy of human placenta-derived  
24 mesenchymal stem cells by chemical isotope labeling LC–MS. *Experimental Cell Research*,  
25 372(1), 52–60. <https://doi.org/10.1016/j.yexcr.2018.09.009>
- 26 63. Folmes, C. D. L., Nelson, T. J., Martinez-Fernandez, A., Arrell, D. K., Lindor, J. Z., Dzeja, P.  
27 P., Ikeda, Y., Perez-Terzic, C., & Terzic, A. (2011). Somatic oxidative bioenergetics transitions  
28 into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. *Cell Metabolism*,  
29 14(2), 264–271. <https://doi.org/10.1016/j.cmet.2011.06.011>
- 30 64. Sherstyuk, V. V., Yanshole, L. V., Zelentsova, E. A., Melnikov, A. D., Medvedev, S. P.,  
31 Tsentelovich, Y. P., & Zakian, S. M. (2020). Comparative Metabolomic Profiling of Rat  
32 Embryonic and Induced Pluripotent Stem Cells. *Stem Cell Reviews and Reports*, 16(6), 1256–  
33 1265. <https://doi.org/10.1007/s12015-020-10052-3>
- 34 65. Park, H., Haynes, C. A., Nairn, A. V., Kulik, M., Dalton, S., Moremen, K., & Merrill, A. H.  
35 (2010). Transcript profiling and lipidomic analysis of ceramide subspecies in mouse embryonic  
36 stem cells and embryoid bodies. *Journal of Lipid Research*, 51(3), 480–489.  
37 <https://doi.org/10.1194/jlr.M000984>
- 38 66. Panopoulos, A. D., Yanes, O., Ruiz, S., Kida, Y. S., Diep, D., Tautenhahn, R., Herrerías, A.,  
39 Batchelder, E. M., Plongthongkum, N., Lutz, M., Berggren, W. T., Zhang, K., Evans, R. M.,



- 1 Siuzdak, G., & Belmonte, J. C. I. (2012). The metabolome of induced pluripotent stem cells  
2 reveals metabolic changes occurring in somatic cell reprogramming. *Cell Research*, 22(1),  
3 168–177. <https://doi.org/10.1038/cr.2011.177>
- 4 67. Wu, Y., Chen, K., Xing, G., Li, L., Ma, B., Hu, Z., Duan, L., & Liu, X. (2019). Phospholipid  
5 remodeling is critical for stem cell pluripotency by facilitating mesenchymal-to-epithelial  
6 transition. *Science Advances*, 5(11), eaax7525 (11 pages).  
7 <https://doi.org/10.1126/sciadv.aax7525>
- 8 68. Meissen, J. K., Yuen, B. T. K., Kind, T., Riggs, J. W., Barupal, D. K., Knoepfler, P. S., &  
9 Fiehn, O. (2012). Induced Pluripotent Stem Cells Show Metabolomic Differences to  
10 Embryonic Stem Cells in Polyunsaturated Phosphatidylcholines and Primary Metabolism.  
11 *PLoS ONE*, 7(10), e46770 (9 pages). <https://doi.org/10.1371/journal.pone.0046770>
- 12 69. Park, S. J., Lee, S. A., Prasain, N., Bae, D., Kang, H., Ha, T., Kim, J. S., Hong, K. S., Mantel,  
13 C., Moon, S. H., Broxmeyer, H. E., & Lee, M. R. (2017). Metabolome Profiling of Partial and  
14 Fully Reprogrammed Induced Pluripotent Stem Cells. *Stem Cells and Development*, 26(10),  
15 734–742. <https://doi.org/10.1089/scd.2016.0320>
- 16 70. Nagasaka, R., Gotou, Y., Yoshida, K., Kanie, K., Shimizu, K., Honda, H., & Kato, R. (2017).  
17 Image-based cell quality evaluation to detect irregularities under same culture process of  
18 human induced pluripotent stem cells. *Journal of Bioscience and Bioengineering*, 123(5), 642–  
19 650. <https://doi.org/10.1016/j.jbiosc.2016.12.015>
- 20 71. Vernardis, S. I., Terzoudis, K., Panoskaltsis, N., & Mantalaris, A. (2017). Human embryonic  
21 and induced pluripotent stem cells maintain phenotype but alter their metabolism after  
22 exposure to ROCK inhibitor. *Scientific Reports*, 7(October 2016), 42138 (11 pages).  
23 <https://doi.org/10.1038/srep42138>
- 24 72. Tanosaki, S., Tohyama, S., Fujita, J., Someya, S., Hishiki, T., Matsuura, T., Nakanishi, H.,  
25 Ohto-Nakanishi, T., Akiyama, T., Morita, Y., Kishino, Y., Okada, M., Tani, H., Soma, Y.,  
26 Nakajima, K., Kanazawa, H., Sugimoto, M., Ko, M. S. H., Suematsu, M., Fukuda, K. (2020).  
27 Fatty Acid Synthesis Is Indispensable for Survival of Human Pluripotent Stem Cells. *iScience*,  
28 23(9), 101535 (13 pages). <https://doi.org/10.1016/j.isci.2020.101535>
- 29 73. Yanes, O., Clark, J., Wong, D. M., Patti, G. J., Sánchez-Ruiz, A., Benton, H. P., Trauger, S. A.,  
30 Desponts, C., Ding, S., & Siuzdak, G. (2010). Metabolic oxidation regulates embryonic stem  
31 cell differentiation. *Nature Chemical Biology*, 6(6), 411–417.  
32 <https://doi.org/10.1038/nchembio.364>
- 33 74. Patsch, C., Challet-Meylan, L., Thoma, E. C., Urich, E., Heckel, T., O’Sullivan, J. F., Grainger,  
34 S. J., Kapp, F. G., Sun, L., Christensen, K., Xia, Y., Florido, M. H. C., He, W., Pan, W.,  
35 Prummer, M., Warren, C. R., Jakob-Roetne, R., Certa, U., Jagasia, R., Freskgard, P., Adatto, I.,  
36 Kling, D., Huang, P., Zon, L. I., Chaikof, E. L., Gerszten, R. E., Graf, M., Iacone, R., Cowan,  
37 C. A. (2015). Generation of vascular endothelial and smooth muscle cells from human  
38 pluripotent stem cells. *Nature Cell Biology*, 17(8), eaax7525 (6 pages).  
39 <https://doi.org/10.1038/ncb3205>

- 1 75. Danoy, M., Poulain, S., Jelalli, R., Gilard, F., Kato, S., Plessy, C., Kido, T., Miyajima, A.,  
2 Sakai, Y., & Leclerc, E. (2020). Integration of metabolomic and transcriptomic profiles of  
3 hiPSCs-derived hepatocytes in a microfluidic environment. *Biochemical Engineering Journal*,  
4 *155*(January), 107490. <https://doi.org/10.1016/j.bej.2020.107490>
- 5 76. Pöhö, P., Lipponen, K., Bessalov, M. M., Sikanen, T., Kotiaho, T., & Kostianen, R. (2019).  
6 Comparison of liquid chromatography-mass spectrometry and direct infusion microchip  
7 electrospray ionization mass spectrometry in global metabolomics of cell samples. *European*  
8 *Journal of Pharmaceutical Sciences*, *138*, 104991 (7 pages).  
9 <https://doi.org/10.1016/j.ejps.2019.104991>
- 10 77. Elena-Herrmann, B., Montellier, E., Fages, A., Bruck-Haimson, R., & Moussaieff, A. (2020).  
11 Multi-platform NMR Study of Pluripotent Stem Cells Unveils Complementary Metabolic  
12 Signatures towards Differentiation. *Scientific Reports*, *10*(1), 1622 (11 pages).  
13 <https://doi.org/10.1038/s41598-020-58377-w>
- 14 78. Hsu, C. C., Xu, J., Brinkhof, B., Wang, H., Cui, Z., Huang, W. E., & Ye, H. (2020). A single-  
15 cell Raman-based platform to identify developmental stages of human pluripotent stem cell-  
16 derived neurons. *Proceedings of the National Academy of Sciences of the United States of*  
17 *America*, *117*(31), 18412–18423. <https://doi.org/10.1073/pnas.2001906117>
- 18 79. Nakamura, Y., Shimizu, Y., Horibata, Y., Tei, R., Koike, R., Masawa, M., Watanabe, T.,  
19 Shiobara, T., Arai, R., Chibana, K., Takemasa, A., Sugimoto, H., & Ishii, Y. (2017). Changes  
20 of plasmalogen phospholipid levels during differentiation of induced pluripotent stem cells  
21 409B2 to endothelial phenotype cells. *Scientific Reports*, *7*(1), 9377 (9 pages).  
22 <https://doi.org/10.1038/s41598-017-09980-x>
- 23 80. Tohyama, S., Fujita, J., Hishiki, T., Matsuura, T., Hattori, F., Ohno, R., Kanazawa, H., Seki, T.,  
24 Nakajima, K., Kishino, Y., Okada, M., Hirano, A., Kuroda, T., Yasuda, S., Sato, Y., Yuasa, S.,  
25 Sano, M., Suematsu, M., Fukuda, K. (2016). Glutamine Oxidation Is Indispensable for Survival  
26 of Human Pluripotent Stem Cells. *Cell Metabolism*, *23*(4), 663–674.  
27 <https://doi.org/10.1016/j.cmet.2016.03.001>
- 28 81. D’Aniello, C., Habibi, E., Cermola, F., Paris, D., Russo, F., Fiorenzano, A., Di Napoli, G.,  
29 Melck, D. J., Cobellis, G., Angelini, C., Fico, A., Belloch, R., Motta, A., Stunnenberg, H. G.,  
30 De Cesare, D., Patriarca, E. J., & Minchiotti, G. (2017). Vitamin C and L-Proline Antagonistic  
31 Effects Capture Alternative States in the Pluripotency Continuum. *Stem Cell Reports*, *8*(1), 1–  
32 10. <https://doi.org/10.1016/j.stemcr.2016.11.011>
- 33 82. Zhao, X., Chen, H., Xiao, D., Yang, H., Itzhaki, I., Qin, X., Chour, T., Aguirre, A., Lehmann,  
34 K., Kim, Y., Shukla, P., Holmström, A., Zhang, J. Z., Zhuge, Y., Ndoeye, B. C., Zhao, M.,  
35 Neofytou, E., Zimmermann, W. H., Jain, M., Wu, J. C. (2018). Comparison of Non-human  
36 Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment  
37 of Myocardial Infarction. *Stem Cell Reports*, *10*(2), 422–435.  
38 <https://doi.org/10.1016/j.stemcr.2018.01.002>
- 39 83. Rohani, L., Borys, B. S., Razian, G., Naghsh, P., Liu, S., Johnson, A. A., Machiraju, P.,

- 1 Holland, H., Lewis, I. A., Groves, R. A., Toms, D., Gordon, P. M. K., Li, J. W., So, T., Dang,  
2 T., Kallos, M. S., & Rancourt, D. E. (2020). Stirred suspension bioreactors maintain naïve  
3 pluripotency of human pluripotent stem cells. *Communications Biology*, 3(1), 492 (22 pages).  
4 <https://doi.org/10.1038/s42003-020-01218-3>
- 5 84. Ismailoglu, I., Chen, Q., Popowski, M., Yang, L., Gross, S. S., & Brivanlou, A. H. (2014).  
6 Huntingtin protein is essential for mitochondrial metabolism, bioenergetics and structure in  
7 murine embryonic stem cells. *Developmental Biology*, 391(2), 230–240.  
8 <https://doi.org/10.1016/j.ydbio.2014.04.005>
- 9 85. Sato, Y., Kobayashi, H., Higuchi, T., Shimada, Y., Ida, H., & Ohashi, T. (2017). Metabolomic  
10 Profiling of Pompe Disease-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals  
11 That Oxidative Stress Is Associated with Cardiac and Skeletal Muscle Pathology. *STEM*  
12 *CELLS Translational Medicine*, 6(1), 31–39. <https://doi.org/10.5966/sctm.2015-0409>
- 13 86. Yoshida, T., Awaya, T., Jonouchi, T., Kimura, R., Kimura, S., Era, T., Heike, T., & Sakurai, H.  
14 (2017). A skeletal muscle model of infantile-onset pompe disease with patient-specific iPS  
15 cells. *Scientific Reports*, 7(1), 13473 (13 pages). <https://doi.org/10.1038/s41598-017-14063-y>
- 16 87. Warren, C. R., O’Sullivan, J. F., Friesen, M., Becker, C. E., Zhang, X., Liu, P., Wakabayashi,  
17 Y., Morningstar, J. E., Shi, X., Choi, J., Xia, F., Peters, D. T., Florido, M. H. C., Tsankov, A.  
18 M., Duberow, E., Comisar, L., Shay, J., Jiang, X., Meissner, A., Musunuru, K., Kathiresan, S.,  
19 Daheron, L., Zhu, J., Gerszten, R. E., Deo, R. C., Vasam, R. S., O’Donnell, C. J., Cowan, C. A.  
20 (2017). Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS  
21 Variants in Metabolic Disease. *Cell Stem Cell*, 20(4), 547–557.  
22 <https://doi.org/10.1016/j.stem.2017.01.010>
- 23 88. Kim, J., Kang, S. C., Yoon, N. E., Kim, Y., Choi, J., Park, N., Jung, H., Jung, B. H., & Ju, J. H.  
24 (2019). Metabolomic profiles of induced pluripotent stem cells derived from patients with  
25 rheumatoid arthritis and osteoarthritis. *Stem Cell Research and Therapy*, 10(1), 319 (13 pages).  
26 <https://doi.org/10.1186/s13287-019-1408-5>
- 27 89. Castiglione, F., Ferro, M., Mavroudakis, E., Pellitteri, R., Bossolasco, P., Zaccheo, D.,  
28 Morbidelli, M., Silani, V., Mele, A., Moscatelli, D., & Cova, L. (2017). NMR Metabolomics  
29 for Stem Cell type discrimination. *Scientific Reports*, 7(1), 15808 (12 pages).  
30 <https://doi.org/10.1038/s41598-017-16043-8>
- 31 90. Lee, H., Lee, H. R., Kim, H. Y., Lee, H., Kim, H. J., & Choi, H. K. (2019). Characterization  
32 and classification of rat neural stem cells and differentiated cells by comparative metabolic and  
33 lipidomic profiling. *Analytical and Bioanalytical Chemistry*, 411(21), 5423–5436.  
34 <https://doi.org/10.1007/s00216-019-01922-y>
- 35 91. Drago, D., Basso, V., Gaude, E., Volpe, G., Peruzzotti-Jametti, L., Bachi, A., Musco, G.,  
36 Andolfo, A., Frezza, C., Mondino, A., & Pluchino, S. (2016). Metabolic determinants of the  
37 immune modulatory function of neural stem cells. *Journal of Neuroinflammation*, 13(1), 232  
38 (18 pages). <https://doi.org/10.1186/s12974-016-0667-7>
- 39 92. Baumann, H. J., Betonio, P., Abeywickrama, C. S., Shriver, L. P., & Leipzig, N. D. (2020).

- 1 Metabolomic and Signaling Programs Induced by Immobilized versus Soluble IFN  $\gamma$  in Neural  
2 Stem Cells. *Bioconjugate Chemistry*, 31(9), 2125–2135.  
3 <https://doi.org/10.1021/acs.bioconjchem.0c00338>
- 4 93. Fang, Q., Zhang, Y., Chen, X., Li, H., Cheng, L., Zhu, W., Zhang, Z., Tang, M., Liu, W.,  
5 Wang, H., Wang, T., Shen, T., & Chai, R. (2020). Three-Dimensional Graphene Enhances  
6 Neural Stem Cell Proliferation Through Metabolic Regulation. *Frontiers in Bioengineering  
7 and Biotechnology*, 7, 436 (14 pages). <https://doi.org/10.3389/fbioe.2019.00436>
- 8 94. Alakpa, E. V., Jayawarna, V., Lampel, A., Burgess, K. V., West, C. C., Bakker, S. C. J., Roy,  
9 S., Javid, N., Fleming, S., Lamprou, D. A., Yang, J., Miller, A., Urquhart, A. J., Frederix, P. W.  
10 J. M., Hunt, N. T., Péault, B., Ulijn, R. V., & Dalby, M. J. (2016). Tunable Supramolecular  
11 Hydrogels for Selection of Lineage-Guiding Metabolites in Stem Cell Cultures. *Chem*, 1(2),  
12 298–319. <https://doi.org/10.1016/j.chempr.2016.07.001>
- 13 95. Alakpa, E. V., Jayawarna, V., Burgess, K. E. V., West, C. C., Péault, B., Ulijn, R. V., & Dalby,  
14 M. J. (2017). Improving cartilage phenotype from differentiated pericytes in tunable peptide  
15 hydrogels. *Scientific Reports*, 7(1), 6895 (11 pages). <https://doi.org/10.1038/s41598-017-07255-z>
- 17 96. Agathocleous, M., Meacham, C. E., Burgess, R. J., Piskounova, E., Zhao, Z., Crane, G. M.,  
18 Cowin, B. L., Bruner, E., Murphy, M. M., Chen, W., Spangrude, G. J., Hu, Z., DeBerardinis,  
19 R. J., & Morrison, S. J. (2017). Ascorbate regulates haematopoietic stem cell function and  
20 leukaemogenesis. *Nature*, 549(7673), 476–481. <https://doi.org/10.1038/nature23876>
- 21 97. Kumar, A., Kumar, Y., Sevak, J. K., Kumar, S., Kumar, N., & Gopinath, S. D. (2020).  
22 Metabolomic analysis of primary human skeletal muscle cells during myogenic progression.  
23 *Scientific Reports*, 10(1), 11824 (14 pages). <https://doi.org/10.1038/s41598-020-68796-4>
- 24 98. Rudan, M. V., Mishra, A., Klose, C., Eggert, U. S., & Watt, F. M. (2020). Human epidermal  
25 stem cell differentiation is modulated by specific lipid subspecies. *Proceedings of the National  
26 Academy of Sciences of the United States of America*, 117(36), 22173–22182.  
27 <https://doi.org/10.1073/pnas.2011310117>
- 28 99. Turner, W. S., Seagle, C., Galanko, J. A., Favorov, O., Prestwich, G. D., Macdonald, J. M., &  
29 Reid, L. M. (2008). Nuclear Magnetic Resonance Metabolomic Footprinting of Human Hepatic  
30 Stem Cells and Hepatoblasts Cultured in Hyaluronan-Matrix Hydrogels. *Stem Cells*, 26(6),  
31 1547–1555. <https://doi.org/10.1634/stemcells.2007-0863>
- 32 100. Costantini, D., Overi, D., Casadei, L., Cardinale, V., Nevi, L., Carpino, G., Di Matteo, S.,  
33 Safarikia, S., Valerio, M., Melandro, F., Bizzarri, M., Manetti, C., Berloco, P. B., Gaudio, E.,  
34 & Alvaro, D. (2019). Simulated microgravity promotes the formation of tridimensional  
35 cultures and stimulates pluripotency and a glycolytic metabolism in human hepatic and biliary  
36 tree stem/progenitor cells. *Scientific Reports*, 9(1), 5559 (10 pages).  
37 <https://doi.org/10.1038/s41598-019-41908-5>
- 38 101. Li, B.-B., Chen, Z. Y., Jiang, N., Guo, S., Yang, J. Q., Chai, S. Bin, Yan, H. F., Sun, P. M., Hu,  
39 G., Zhang, T., Xu, B. X., Sun, H. W., Zhou, J. L., Yang, H. M., & Cui, Y. (2020). Simulated

- 1 microgravity significantly altered metabolism in epidermal stem cells. *In Vitro Cellular and*  
2 *Developmental Biology - Animal*, 56(3), 200–212. <https://doi.org/10.1007/s11626-020-00435-8>
- 3 102. Takubo, K., Nagamatsu, G., Kobayashi, C. I., Nakamura-Ishizu, A., Kobayashi, H., Ikeda, E.,  
4 Goda, N., Rahimi, Y., Johnson, R. S., Soga, T., Hirao, A., Suematsu, M., & Suda, T. (2013).  
5 Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence  
6 in hematopoietic stem cells. *Cell Stem Cell*, 12(1), 49–61.  
7 <https://doi.org/10.1016/j.stem.2012.10.011>
- 8 103. Xu, B., Wei, X., Chen, M., Xie, K., Zhang, Y., Huang, Z., Dong, T., Hu, W., Zhou, K., Han,  
9 X., Wu, X., & Xia, Y. (2019). Glycylglycine plays critical roles in the proliferation of  
10 spermatogonial stem cells. *Molecular Medicine Reports*, 20(4), 3802–3810.  
11 <https://doi.org/10.3892/mmr.2019.10609>
- 12